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Thyroid hormones (THs) in mammalian tissues are crucial for development and maintaining 
metabolic homeostasis. Iodothyronine deiodinases (Dios) remove iodines from THs by a selenocysteine 
(Sec) residue, which either activates or inactivates them. Halogen bonding (XB) has been proposed to 
describe the interaction between the Se and I atoms of the T4-Dio complex. Disruption of TH homeostasis 
by xenobiotics, such as polybrominated diphenyl ethers (PBDEs) and polychlorinated biphenyls (PCBs) 
can cause deleterious effects on the endocrine system. Experimental studies have indicated that PBDEs 
and PCBs could disrupt TH homeostasis by inhibiting Dio through XB formation. However, no current 
quantitative study exists that compares the relative strengths of PBDE and PCB XB strengths. Trends in 
XB interactions of a small model of the active site (MeSe-) with THs and potential inhibitors PBDEs and 
PCBs are analyzed using density functional theory (DFT). In agreement with trends in XB, XB 
favorability follows in the order of THs > PBDEs > PCBs (i.e., I > Br > Cl). Highly brominated PBDEs 
show similar interaction energies to THs, suggesting possible inhibition and debromination of these 
compounds.  
Schweizer et al. solved the crystal structure of the monomeric catalytic domain of Dio3. 
However, Dio3 must dimerize in order to perform catalytic deiodination, and no structural data currently 
exists regarding a Dio3 dimer. A debate between two groups has been ongoing in the literature regarding 
how Dio3 undergoes dimerization. Proposed Dio3 dimer structures by Sagar and Schweizer may be 
attributed to the observance of A-type and B-type dimers within peroxiredoxins (Prxs). Sequential 
comparisons using Clustal Omega of Dio3 to known A-type and B-type dimers show the B-type 
dimerization dimerization is more plausible for Dio3. In silico protein-protein docking databases 
 
 
SymmDock and GalaxyRefineComplex were employed to successfully construct a Dio3 dimer based 
upon the B-type description. The refined Dio3 dimer was subject to MD simulations to test for the 
stability of the dimer. MMGBSA calculations show formation of the dimer is stable and interdimer 
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Thyroid hormones (THs) were first isolated by Edward Calvin Kendall in 1915. He was 
eventually awarded (along with his colleagues Tadeusz Reichstein and Phillip Hench) a Nobel Prize in 
Physiology and Medicine for his contribution.1 These biomolecules are essential for many bodily 
processes such as body temperature regulation, digestion, bone growth, and heart rate.2–5 Thyroid 
hormones, in the form of thyroxine (T4) or triiodothyronine (T3), are secreted in a roughly 14:1 ratio from 
the thyroid gland upon binding of a thyroid stimulating hormone (TSH) (Figure 1).6,7 These hormones 
contain the essential trace element iodine, which can be obtained from a diet consisting of vegetables, 
seafood, and iodized table salt.8 Insufficient iodine intake leads to reduced production of thyroid 
hormones, causing hypothyroidism, goiter, and cretinism.9,10 On the other hand, excessive iodine intake 
from diet can lead to a surplus in TH levels, leading to hyperthyroidism, diarrhea, irregular heartbeats 











Fortunately, there are treatments and preventive measures in place for TH imbalances by 
hypothyroidism or hyperthyroidism. Incorporating iodine into foods, such as by adding salt, can ensure an 
adequate amount of iodine is available for TH production. In more severe cases of hypothyroidism, 
combination therapy, which uses levothyroxine (L-thyroxine) and liothyronine (synthetic T3), has shown 
some improvement in the well-being of patients, however clinical trials have generally failed to show a 
noticeable benefit.12,13 In the case of hyperthyroidism, avoiding foods containing high iodine content is 
often advised. Like hypothyroidism, treatments are available for hyperthyroidism. Administration of beta-
blockers such as propranolol are used to suppress the symptoms of hyperthyroidism, however it has been 
shown to be an ineffective treatment long-term.14 In the most extreme cases of hyperthyroidism, 
radioiodine therapy is commonly performed in which iodine-131 is taken orally to completely suppress 
the hyperactive thyroid gland.15 Unfortunately, patients treated using radioiodine therapy have an 
increased risk of cancer in the stomach, kidney and breast.15 Because of the shortcomings of the current 
treatments of hypo- and hyperthyroidism, there is a demand for more effective treatments and/or methods 
to combat TH imbalances. Understanding the underlying causes of TH imbalances will be paramount for 
treating endocrine-related diseases and deficits. 
The synthetic process of THs occurs over multiple steps and involves the hypothalamus, pituitary 
gland, and thyroid gland (Figure 2).2,16,17 First, inorganic iodine is extracted from the bloodstream into the 
thyroid follicular cell by a unique transport system mediated by the sodium iodide symporter (NIS).18 The 
inorganic iodine is then transported through the thyroid follicular cells into the thyroid gland, binding to 
heme-containing thyroid peroxidase (TPO).19 TPO is an enzyme within the thyroid gland that begins the 
organification process of iodines for use in THs. During iodine extraction, peroxidases (DUOX1 and 
DUOX2) generate hydrogen peroxide (H2O2).20 H2O2 aids in iodination and phenolic coupling of tyrosyl 
ends of thyroglobulin (Tg) with TPO to form the Tg-T4/T3 complex.20 The Tg-T4/T3 complexes are stored 
in the follicular lumen.2 As TSH concentration increases, the Tg-T4/T3 complexes are slowly moved from 
the lumen into the follicular cells. The T4 and T3 residues are then cleaved from the Tg by proteolysis in 
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preparation for secretion.2 Upon secretion, THs bind to transport proteins (TPs) such as transthyretin 
(TTR) or thyroglobulin (TBG) to be transported to various tissues to perform a variety of functions. For 
example, THs can be transported to the heart to regulate heart rate, or they can be transported to the liver 



























































Figure 3. Overview of the general mechanistic pathway of TH transport. Adapted from ref. 2. 
 
 
When THs reach their designated location, they may be metabolized in many ways.21 Sulfation or 
glucuronidation of THs by cytosolic sulfotransferases (SULTs) or 5’-diphosphate-
glucuronosyltransferases (UGTs) inactivates THs.22 These pathways are considered ‘reservoirs’ for the 
active thyroid hormones, as both processes are reversible.22 THs can also be deaminated or 
decarboxylated to form iodothyroacetic acids or iodothyronamines (TAMs) respectively (Figure 4).23,24 
Decarboxylation of THs to TAMs is a common pathway in the brain, as TAMs bind to trace amine-
associated receptors (TAARs) to ease neurotransmitter usage.25–27 On the other hand, in vivo studies of 
iodothyroacetic acids (TA4 or Tetrac) show these compounds suppress TH secretion by inhibiting  
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receptor sites on TSH.28 Finally, THs can have their iodines removed by iodothyronine deiodinases 




Figure 4. Pathways of metabolism of THs. 
 
 
 Dios constitute three separate proteins, Dio1, Dio2 and Dio3, that are encoded by separate genes 
and each is involved in regioselective deiodination of THs.29 These proteins have been studied for nearly 
half a century and the roles and features of these proteins are well-defined. The most notable feature of 
these proteins is that they are classified as selenoenzymes, meaning they contain a selenocysteine (Sec) 
residue embedded within the active site.30 The Sec residue has been proposed to directly participate in 
deiodination, and mutation of Sec either reduces or completely suppresses Dio activity.31 In vertebrates, 
Dio2 and Dio3 are highly expressed during developmental stages and are essential for regulating TH 
levels in tissues and the bloodstream.32 Overexpression of Dio activity has been implicated in disease 
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states. For example, excessive Dio3 activity leads to consumptive hypothyroidism, where the production 
of T3 becomes much faster than the ability of the thyroid gland to secrete THs.33 Consumptive 
hypothyroidism can lead to many ailments, including increased weight gain, depression, and goiter.34  
Structurally, all Dios adopt a thioredoxin (Trx) fold and have a Dio-insertion region between β2 and αD 
that is overlooked by an unstructured loop-D. Loop-D has been proposed to aid substrate binding due to 
its proximity to the active site.35 This unstructured loop region has a conserved N-terminal AHxxDGW 
sequence across the Dio family, however the length and sequence of the loops vary greatly.36 Halogen 
bonding (XB) has been proposed as a mechanism in which Dio removes an iodine from THs through 
formation of a strong Se—I bond between a TH iodine and the Sec selenium.37 XB is supported 
experimentally through a study involving naphthyl-based deiodinase mimics which show deiodination 
activity through chalcogen and halogen bonding and by the crystal structure of monomeric Dio3.35,38  
One area to be addressed in this study is how endocrine disrupting chemicals (EDCs), such as 
polybrominated diphenyl ethers (PBDEs) and polychlorinated biphenyls (PCBs), affect Dio activity. 
PBDEs and PCBs are used primarily in commercialized products to increase flame resistance.39,40 Excess 
intake of organohalogen EDCs has been shown to have long-term negative health effects such as 
cardiovascular diseases and hypo/hyperthyroidism.2,6 Prenatal exposure to EDCs has been associated with 
impaired thyroid function, leading to lower levels of free T4 and T3 in circulation.41 In addition, industrial 
runoff of these PCBs has shown to contaminate the Michigan water supply, which has led to a civil court 
case of Michigan v. Robert Massey over a violation of the Clean Water Act.42 Experimental studies have 
shown these EDCs can suppress Dio activity leading to decreased serum T3 and rT3 levels.43–45 EDCs 
could form X—Se XB interactions to active site Sec similar to THs. However, no quantitative study 
currently exists in the literature that compares the relative strengths of the interactions between EDCs and 
Dio.  
Another problem regarding research on Dio3 is the lack of a solved dimeric structure of Dio3. 
While structural data exists for monomeric Dio3, this is the inactive form of the protein. An experimental 
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study involving fluorescence resonance energy transfer (FRET) shows Dio3 is catalytically active only as 
a homodimer.46 In addition, within the literature, there are conflicting viewpoints regarding the interface 
of the Dio3 dimer.35,47 Resolving a dimeric structure based upon the isolated monomeric structure of the 
catalytic region would be an essential first step to help expand our understanding of the structural and 
catalytic aspects of Dio3. 
In this dissertation, computational (i.e., in silico) methods are used to determine and identify the 
key interactions between Dio and halogenated aromatics and potential Dio inhibitors (THs, PBDEs, 
PCBs) on an atomistic level. In silico techniques have two distinct advantages over experimental 
methods. Biochemical systems can be viewed at the atomistic level, which allows key interactions within 
systems, such as salt bridges, hydrogen bonds, and van der Waals interactions to be easily identified. 
Visualization programs such as Visual Molecular Dynamics (VMD), CHIMERA, and Pymol are 
commonly used for inspection of proteins and biochemical systems.48–50 In silico techniques also have the 
advantage of being highly flexible and/or adaptable. A user can ‘fine-tune’ the parameters of a system, 
such as temperature, pH, volume, pressure, and salt concentration, to emulate typical experimental 
conditions of a given system. In silico techniques are also useful for predicting the efficacy of small 
molecules of a given biological system before they are synthesized.51,52 A combination of in silico 
methods, Density Functional Theory and Molecular Dynamics, have been employed to visualize and 
describe XB interactions within Dio. 
Density Functional Theory (DFT) is a quantum-mechanical computational technique first derived 
in the 1960s by Hohenberg and Kohn.53 Although DFT was technically first described by Thomas and 
Fermi in the 1920s, the applications were largely limited due to electron correlation being neglected.54 
DFT has been shown over the past three decades to be versatile and have growing applications in the 
areas of computational physics, computational chemistry, and material sciences. The mathematical basis 
of DFT is summarized via the Hohenberg and Kohn (H-K) theorem.53 The theorem states the structural 
and electronic properties of many-atom systems can be described quantum mechanically by using 
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functionals of the electron density.53 Hohenberg and Kohn considered a system enclosed in a box with an 
arbitrary number of electrons and moving with the external potential function  and repulsive forces.  
The resulting Hamiltonian and the corresponding terms are given below (eqs. 1-4): 
 =  + 
 +                                                                     (1) 
 =  


 ∇∗ ∇                                                    (2) 

 =  ∗                                                     (3) 






∗ ∗′′′                      (4) 
The authors then showed that in the ground state , the electron density of the system can be written as 
eq (5), which shows the electron density  is a functional of the external potential : 
 = , ∗                                        (5) 
  Within DFT, natural bond orbital (NBO) theory emerged as a method for analyzing hybridization 
and covalency effects in polyatomic molecules.55,56 The input atomic orbital (AO) basis set (χi) undergoes 
a series of transformations to distinct localized basis sets through natural atomic orbitals (NAOs) and 
natural hybrid orbitals (NHOs), which is automated through the use of the NBO program in the 
Gaussian09 software package.57 NBOs are the calculated bonding orbitals with the highest possible 
electron density, giving the most accurate representation of  for a system.55 NBO calculations were used 
previously to quantitatively assess XB strengths of Dio model complexes to THs in terms of donor-
acceptor (ΔED→A) energies.37 ΔED→A  energies are correlated to the mixing of the lone-pair orbital 
fragment of a nucleophilic base and an antibonding σ* R-X orbital, which results in a stronger XB 
interaction. Methyl selenolate (MeSe-) was found to form the strongest interaction to the TH model 
compounds by roughly 25 kcal mol-1.37 In this dissertation, NBO calculations were performed using the 
same MeSe- donor to PBDEs and PCBs and were compared to THs to see the overall trends in XB 
strengths across all three groups. In addition, NBO analysis was used to assess how substitution patterns 
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(ortho, meta, para) or degree of halogenation affected the relative XB strengths within each grouping. For 
these DFT calculations, the MPW1PW91 and M062X functionals were employed, which have been 
shown by display a high level of accuracy over a variety of systems.58  
 Molecular Mechanics (MM) is a computational technique that approximates motions of atoms 
and molecules using classical Newtonian mechanics.59 Quantum mechanical motions of large systems are 
too complex to calculate for even the best supercomputers. MM bypasses the barrier of calculating 
quantum-mechanical motions by instead treating the system via molecular mechanics as shown in eq (6):  
 =  ∑ " − $%&'() + ∑ "*+ − +$%', $) + ∑
-.










 ]                                        (6) 
where the first two terms represent the van der Waals contributions from individual bonds, angles, and 
dihedrals between atoms. The latter term, the Lennard-Jones potential, takes into account the Coulombic 
(electrostatic) interactions of the system.60 Bonds and angles between atoms are treated as virtual springs, 
while dihedral angles are represented by sinusoidal functions that account for energetic differences 
between staggered and eclipsed conformations.61 These forces are often parameterized to agree with 
known experimental structures, such as NMR or spectroscopic data. Parameterization is needed to 
identify ideal charges of atoms, van der Waal radii of atoms, and length and stiffness of springs, which in 
turn describes the ‘force field’.61 Many different force fields, such as  CHARMM, GROMOS, and 
AMBER, are implemented within MD simulation packages and have steadily improved in accuracy.62–69 
The primary application of MM is in molecular dynamics (MD), which is an in silico simulation-based 
method to track and analyze the motions of atoms and molecules within a given system. 
 To carry out an MD simulation, an initial model of a protein or molecule (usually a crystal or an 
NMR structure, although other initial structures or models can be used) is placed in solution, typically 
water. As the MD simulation is carried out, the atoms of the system move according to eq (6), which 
produces a trajectory of the system. This in turn advances the time of the simulation, which is dependent 
on the step size of the system. These steps are typically on the order of femtoseconds or nanoseconds 
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depending on accuracy. This process is repeated millions to billions of times depending on simulation 
length, which often require computer clusters or supercomputers to run the calculations in a timely 
manner. These trajectories can then be viewed by a visualization program such as Visual Molecular 
Dynamics (VMD), CHIMERA, or Pymol.48–50 MD simulations of dimeric Dio3 could provide insight into 
what  the key residue(s) are that hold the dimer interface together and how they change over the course of 
the simulation. Data can be extracted from the trajectory files, such as hydrogen bonding distances, by 
using CPPTRAJ, which is the main program used by AMBER to process trajectory files.70 Overall protein 
and individual residue movements can be determined by plotting the root mean square deviation (RMSD) 
or the root mean square fluctuation (RMSF) respectively. RMSD calculations can be used to determine 
the stability of the Dio3 dimer over the course of a simulation. Hydrogen bond breaking or formation over 
an MD simulation can be tracked via distance plots and can identify the persistent hydrogen bonding 
interactions in the Dio3 dimer.  
In summary, this dissertation attempts to tackle two main questions: 1) can in silico methods be 
used to model XB interactions of PBDEs and PCBs to a small model of the Dio3 active site, and how do 
the substitutional preferences (ortho, meta, para) and degree of halogenation affect the strength of the XB 
interaction; 2) given the crystal structure of monomeric Dio3, can a dimer of Dio3 be constructed using 
known in silico protein-protein docking databases, and what are the key interactions that hold the dimer 
together during an MD simulation. This dissertation is divided into three separate chapters: Chapter 2 
discusses halogen bonding of PBDEs to a small model of the active site of Dio3 using DFT. Chapter 3 
extends the application of Chapter 2 towards PCB XB interactions to a small model of the active site of 
Dio3 using DFT. Chapter 4 compares the recently solved crystal structure of Dio3 to those of other 
thioredoxin-fold dimers along with the results of MD simulations of constructed Dio3 dimers using in 






HALOGEN BONDING INTERACTIONS OF POLYBROMINATED DIPHENYL ETHERS AND 




Thyroid hormones (THs) play a crucial role in neurodevelopment, particularly in the early stages 
of life.2–4,17,71,72 The thyroid pro-hormone thyroxine (T4) and, to a lesser extent, the active triiodothyronine 
(T3) are synthesized in the thyroid by iodination of the amino acid tyrosine by thyroglobulin (TBG).73,74 
THs are secreted upon stimulation by thyroid stimulating hormone (TSH).75 T4 is transported to target 
cells based on metabolic and/or developmental needs and activated by the iodothyronine deiodinase (Dio) 
family of selenoproteins. Three Dio classes regioselectively deiodinate TH derivatives to maintain TH 
homeostasis which is essential for many functions such as regulation of body temperature, bone growth, 
heart rate, and digestion.76,77 Dio1 deiodinates both the inner and outer rings of T4 to form the active 
hormone T3 and the inactive hormone rT3, respectively.78,79 Dio2 is specific to the outer ring deiodination, 
and Dio3 targets only the inner ring (Figure 5). T3 and rT3 can undergo further deiodination to 
diiodothyronines (3,3’-T2, 3,5- T2, or 3’,5’-T2) depending on mechanism of deiodination. The 3,5-T2 
isomer exhibits thyromimetic properties and activates thyroid receptors (TRs) to allow for T4 transport 
and to maintain TH homeostasis.2,80,81 Further order deiodinations can produce lower-order mono- and 
diiodinated THs.2 Disruption of TH homeostasis causes severe side effects such as structural 
abnormalities, hearing loss, cardiovascular diseases, and hypothyroidism.82–87 
                                                           




Figure 5. Pathways for deiodination of THs by the iodothyronine deiodinase family of selenoproteins. 
 
 
Polybrominated diphenyl ethers (PBDEs) are well-known TH disruptors88–90 and are widely used 
in various household products to increase flame resistance.91 Humans are exposed to PBDEs via 
inhalation or ingestion of contaminated house dust.45 Bioaccumulation in breast milk can cause adverse 
developmental effects for the nursing child.92 As a result, many formulations of PBDEs have been 
banned.89 Although PBDEs have been implicated in neurotoxicity, the mechanism of disruption has yet to 
be determined, although many theories have emerged.93 For example, PBDEs and their hydroxylated 
metabolites (OH-BDEs), in particular, may interfere with T4 transport by interacting with transport 
proteins, such as transthyretin (TTR, Figure 6A).94,95 Studies in fish have suggested higher-order PBDEs 
(> 5 Br) are debrominated by Dio proteins to form lower-order BDEs,96,97 the most potent congeners for 
neurotoxicity due to efficient bioaccumulation96,98,99 and mobility through the atmosphere.96,97,100,101 
Alternatively, the competitive inhibition of Dio2 by PBDEs and OH-BDEs (Figure 6B)45 may disrupt TH 
regulation by blocking access to the active site selenocysteine (Sec170) through a Se—Br halogen 
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bonding (XB) interaction. Our group has proposed a mechanism for deiodination by Dio based upon an 
initial Se—I XB intermediate between the TH and the selenocysteine residue at the Dio active site.37 
Subsequent experimental studies have supported this novel mechanism, as has the interpretation of the 




Figure 6. A) PBDE/OH-BDEs inhibit T4 binding to transport protein transthyretin (TTR); B) PBDE/OH-
BDEs inhibit deiodination of T4 to T3 by competitive inhibition to Dio2. 
 
 
XB is an intermolecular interaction between a Lewis base (typically a nucleophile, although there 
are some exceptions) and a halogen atom.102,103 The σ-hole model is often used to explain the interaction 
as the attraction of a donor D for a region of positive electrostatic potential on the otherwise electron-
dense halogen.104 Because the σ-hole lies along the bond axis opposite the R group, the R-X—D bond 
angle is approximately 180 degrees. Alternatively, a molecular orbital (MO) model can describe XB in 
terms of the mixing of an antibonding R-X* acceptor orbital and a lone pair (lp) orbital fragment on the 
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donor (Figure 7A).37,105,106 The XB interaction becomes more favorable with weaker R-X bonds, which 
have lower-lying R-X* MOs, and stronger Lewis bases, in which the lp MO is destabilized. Each of these 
effects enhance mixing of the donor and acceptor MOs to strengthen the interaction. From another 
perspective, a valence bond (VB) model describes XB in terms of resonance structures similar to those 
used for three-center-four-electron (3c4e) bonding in hypervalent molecules. Stronger donors and weaker 
R-X bonds increase the admixture of the right-hand resonance structure to strengthen the XB interaction 
(Figure 7B). Stabilization of this resonance structure by protonation to RH results in nucleophilic 
substitution as proposed in our XB-based mechanism.37 In this study, density functional theory (DFT) 
calculations compare and contrast the relative XB interactions of THs, iodinated contrast agents and 




Figure 7. XB interactions as described by A) MO model; B) valence bond model. 
 
 
2.2 Results and Discussion 
Before examining XB to PBDEs/OH-BDEs, we review interactions for various TH derivatives. 
The geometries for XB complexes of MeSe- with each unique iodine center of the TH derivatives were 
calculated at the DFT/mPW1PW91 level (Table 1). From the relative zero-point energies 
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((ΔEZPE=EZPE(MeSe-(TH))-EZPE(MeSe-)-EZPE(TH))) and NBO donor-acceptor energies (ΔED→A), the most 
favorable position for XB depends upon the extent of iodination and is generally stronger for diiodinated 
rings (average ΔEZPE = -29.2 kcal mol-1) than for monoiodinated rings (average ΔEZPE = -25.2 kcal mol-1).  
For example, T3 and rT3 favor XB at the more-substituted inner and outer ring, respectively. Because the 
potential for nucleophilic substitution (i.e. deiodination) should correlate to XB strength, subsequent 
reactions would be predicted to occur at the more-substituted ring to form 3,3’-T2. However, the actual 
regioselectivity will also depend upon interactions of the TH with residues at the Dio active site. XB 
interactions with 3,3’-T2 and 3’,5’-T2 on the outer ring, stabilized by the neighboring hydroxyl group, are 
more favorable than T3, consistent with their ability to regulate T3 levels by binding to Dio3. The THs 
with monoiodinated rings have less favorable interactions compared to THs with diiodinated rings, as can 
be shown with 3-T1 and 3’-T1 (Table 1); the latter is more stable (ΔEZPE = -21.41 kcal mol-1 versus -27.29 
kcal mol-1) consistent with the ability of 3’-T1 to undergo further deiodination to thyronine (T0) while 3-T1 
does not.107 3-T1 constitutes the weakest XB interaction for a TH derivative with the selenolate 
nucleophile, suggesting a threshold interaction strength must be met in order for deiodination to occur.   
 
 
Table 1. Optimized geometries of the TH derivatives, XB position, activation of C-I bond (Δd(C—
I)), XB distance (d(I—Se)), energy of complex formation (ΔEZPE), and donor-acceptor energies 














T4 Inner LUMO 
(-0.06401) 
2.300 (+0.198) 2.917 -29.59 53.58, 4.18[a] 
T4 Outer LUMO+1 
(-0.06632) 
2.282 (+0.169) 2.960 -29.50 45.93, 3.83[a] 
T3 Inner LUMO 
(-0.06370) 
2.299 (+0.197) 2.922 -28.43 52.87, 3.96[a] 
T3 Outer LUMO+2 
(-0.04955) 
2.256 (+0.144) 3.006 -24.84 40.25, 3.03[a] 
rT3 Inner LUMO+2 
(-0.04296) 
2.276 (+0.174) 2.953 -25.14 48.43, 3.17[a] 
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rT3 Outer LUMO 
(-0.06980) 
2.291 (+0.190) 2.946 -33.07 48.98, 4.12[a] 
3,3’-T2 Inner LUMO+2 
(-0.03952) 
2.272 (+0.169) 2.960 -23.56 46.89, 3.20[a] 
3,3’-T2 Outer LUMO 
(-0.05416) 
2.265 (+0.153) 2.990 -28.46 43.06, 3.61[a] 
3,5-T2 Inner LUMO 
(-0.06022) 
2.286 (+0.184) 2.942 -26.61 48.51 
3’,5’-T2 Outer LUMO 
(-0.06672) 
2.287 (+0.173) 2.954 -32.02 47.48 
3-T1 Inner LUMO+1 
(-0.03616) 
2.262 (+0.158) 2.980 -21.41 43.43 
3’-T1 Outer LUMO+1 
(-0.03303) 
2.260 (+0.158) 3.002 -27.29 41.18 
Iopanoic Acid A N/A 2.279 (+0.166) 2.968 -26.83 45.63 
Iopanoic Acid B N/A 2.315 (+0.185) 2.959 -28.10 48.21 
Iopanoic Acid C N/A 2.294 (+0.174) 2.960 -24.31 45.44 
Tyropanoic 
Acid 
A N/A 2.301 (+0.197) 2.912 -29.79 54.12 
Tyropanoic 
Acid 
B N/A 2.341 (+0.221) 2.901 -31.09 56.78 
Tyropanoic 
Acid 
C N/A 2.311 (+0.192) 2.922 -30.79         52.00 
[a] Donor-acceptor interaction energies with MeSeH from Manna et al.108 
 
 
These results are consistent with the findings of Manna et al.,108,109 who modeled the XB 
interaction of THs with methyl selenol (MeSeH) representing Dio. Se—I interactions for T4 and T3 were 
favored to the inner ring albeit with lower interaction energies due to the use of a neutral selenol donor. 
The selenolate is used as a Dio model in this study because SeCys is likely to be deprotonated at normal 
physiological pH. The stronger nucleophilicity of MeSe- produces larger donor-acceptor energies for the 
interaction with MeSe- relative to MeSeH (ΔED→A = 39.3 kcal mol-1 vs 6.5 kcal mol-1).37 
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The trends in XB can be understood in terms of the energy and C-I* character of the TH lowest 
unoccupied molecular orbitals (LUMOs). In agreement with the MO model for XB (Figure 7A), increased 
donation into a lower energy C-I* MO strengthens the I—Se interaction and activates the C-I bond 
leading to lower ΔEZPE and higher ΔED→A values (Table 1).110 ΔEZPEs correlate with the energy of the C-
I*-type LUMOs, which decrease with increased iodination, within each TH analogue (inner-mono < 
outer-mono ≤ outer-di < inner-di). For T4, the LUMO is delocalized over both rings with slightly larger 
C-I* lobes on the inner ring consistent with the slight preference (< 1 kcal mol-1, Table 1) for XB at that 
position in agreement with the ability of Dio1 to deiodinate at either ring (Figure 5) and the selectivity of 
organoselenium Dio mimics.111 However, the specificity of Dio2 for deiodination of the outer ring of T4 
and Dio3 for the inner ring must be governed by additional interactions at the active site. 
In lower-order THs, the LUMO is localized on the diiodinated ring: outer for rT3 and 3’,5’-T2 and 
inner for T3 and 3,5-T2 (Figure 8). The next lowest energy MO with C-I* character tends to be localized 
on the ring opposite the LUMO (Figure 8); T4 has its next lowest C-I*-type MO at LUMO+1, while all 
others are found at LUMO+2. In addition, the energy difference between the LUMO and LUMO+1(+2) is 
smaller for T4 than for other THs. Slight non-linearity in the inner-ring correlation plots (Figure 8) are 
attributed to the less favorable interactions of T4 and T3 with the higher energy LUMO+1(+2) inner-ring 
C-I* MO.                      




Figure 8. LUMOs and next-lowest LUMO energies for TH derivatives, and the correlation of ΔEZPE to 
the LUMO energy. Each TH derivative was grouped based upon the number of iodines on the outer and 
inner rings. Entries marked with an asterisk indicate an interaction with LUMO+1 (T4) or LUMO+2 (T3). 
 
 
For comparison, XB interactions were modeled with two tri-iodinated contrast agents: iopanoic 
acid and tyropanoic acid (Table 1 and Figure 9). The former inhibits T4 expression to treat 
hyperthyroidism and undergoes deiodination by Dio1.112 Tyropanoic acid prevents hepatic binding of 
thyroxine, although its mechanism of inhibition of Dio is not well understood.113 XB on the iodine 
adjacent to the two substituents is favorable for both contrast agents (ΔED→A = 56.78 kcal mol-1 and 48.21 
kcal mol-1, respectively). The results for iopanoic acid are comparable to the other THs, in agreement with 
its ability to undergo deiodination.112 Tyropanoic acid exhibits a strong XB interaction (average ΔEZPE = -
30.56 kcal mol-1) as well as significant activation of the C-I bond (average Δd(C-I) = +0.191 Å). 





Figure 9. Structures of iopanoic acid and tyropanoic acid. 
 
 
Br—Se XB interactions with MeSe- were modeled for a set of four PBDEs used by Roberts et. 
al.45 and 18 OH-BDEs in Yu et. al. (Figure 10, Appendix A).114 XB complexes are designated by the ring 
position at which XB takes place (o, m, or p) using a prime for interactions to the ring opposite the 
hydroxyl group. For example, for XB-o’-3a-OH-BDE-7, XB occurs at the ortho position of 3a-OH-BDE-
7 on the ring opposite the hydroxyl group. XB complexes with MeSe- were calculated for all possible 
interactions of selenium with each unique bromine. In general, XB interactions for the PBDEs and OH-
BDEs were less favorable than the TH derivatives (average ΔEZPE = -18.5 kcal mol-1 vs. -27.6 kcal mol-1). 
In addition, the C-Br bonds of the PBDEs/OH-BDEs are not activated as strongly as for THs (average 
Δd(C-Br) = +0.15 Å; average Δd(C-I) = +0.17 Å). As the Se—Br distance decreases due to a stronger 
interaction, the C-Br bond lengthens resulting in activation of the bond (Figures 11A and 11B). 
Interactions at the ortho and meta positions more strongly activate the C-Br bond compared to the para 
position. This activation corresponds to increased donation of the Se lp orbital into the C-Br* acceptor 
fragment consistent with larger ΔED→A values (Figures 11C and 11D).  In general, higher-order 
brominated compounds exhibit shorter Se—Br distances and increased donation of the Se lp, with the 
decabrominated BDE-209 being a notable exception (Figures 11B and 11D). These results are consistent 
with the trend in C-X bond strength (C-Br > C-I)110 and the absence of debrominated products in the 
studies of Dio2 inhibition by PBDEs.45 In a few cases, the XB interaction to an ortho Br with an ortho 
OH on the opposite ring led to highly activated C-Br bonds (e.g., XB-o’-6-OH-BDE-82: Δd(C-Br) = 
+0.377 Å; ΔEZPE = -21.84 kcal mol-1). The proximity of the OH proton to Br in some OH-BDEs (such as 
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3a-OH-BDE-154) allows for a hydrogen-bonding interaction that stabilizes the partial charge of the 
carbon end of the activated C-Br bond, favoring the right-hand resonance structure of the XB interaction 
(Figure 7B, Figure 9). Although these cases agree with the overall trends found for XB to PBDE/OH-
PBDEs, they were omitted from the following analysis because their interactions were considered 








Figure 11. Comparison of bond distances by A) XB position and B) degree of bromination and donor-
acceptor energy by C) XB position and D) degree of bromination. 
 
 
In general, stronger C-Br bonds have a higher energy C-Br* acceptor MO and weaker XB 
interactions relative to C-I bonds. In a previous study of XB interactions between Me2Se and PhX, the 
less favorable C-Br* MO of PhBr resulted in a smaller ΔED→A than PhI (3.4 vs 7.3 kcal mol-1).37 The 
LUMOs of highly brominated PBDE/OH-PBDEs have C-Br* character (i.e., 6-HO-BDE-157, Figure 12), 
but those with the fewer bromines have π*-type LUMOs with higher energy unoccupied C-Br* LUMOs 
(i.e. 2-HO-BDE-28, 3-HO-BDE-47, Figure 12) resulting in less favorable XB interaction energies and 
less activation of the C-X bond in comparison to the aryliodine derivatives. Increased substitution with 
either -Br or -OH lowers the energy of the C-Br* MO, strengthening the XB interaction. Some highly 
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brominated PBDEs/OH-BDEs have comparable MO energies to the THs and therefore similar XB 




Figure 12. LUMO orbitals containing the lowest energy and the next-lowest energy for 2a-HO-BDE-28 
(4 Brs), 3-HO-BDE-47 (4 Brs), 6-HO-BDE-157 (6 Brs), and 3a-HO-BDE-154 (6 Brs). 
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The XB interactions for the PBDEs/OH-BDEs at each position of the phenylic rings (ortho, meta, 
para) with MeSe- were also compared in terms of activation of the C-X bond and the overall energy in 
terms of ΔEZPE. XB interactions with para positions are generally clustered at low ΔEZPE with a weak 
activation of the C-Br bond (average Δd(C-Br) = +0.118 Å, Figure 13). Ortho- and meta- XB interactions 
tend to have more activated C-Br bonds (average Δd(C-Br) = +0.17 Å and +0.15 Å, respectively), albeit 
over a similar energy range as at the para position. For example, in 3-HO-BDE-47, the C-Br bonds are 
more activated at the ortho positions (average Δd(C-Br) = +0.151 Å) relative to para (average Δd(C-Br) 
= +0.110 Å). These results are consistent with the donor-acceptor energies. The favorability for XB in 
ortho/meta positions in PBDEs/OH-BDEs is consistent with the conserved ortho/meta iodination of THs. 
These important biomolecules may have adopted this regiospecificity due to the higher activation of C-I 
bonds at these positions. Highly active PBDEs/OH-BDEs are likely those whose structural similarity 
allows them to mimic the binding of THs to various proteins.  
The clustering observed in Figure 13 is due to the additional effect of higher order substitution in 
the PBDEs/OH-BDEs. The C-Br bonds tend to be more activated and XB generally more favorable as the 
number of electron-withdrawing substituents increases. Many of the penta- and hexabrominated 
compounds have ΔEZPE and Δd(C-X) values similar to the TH derivatives, consistent with the potential 
for highly substituted PBDEs to undergo debromination as suggested in fish studies.96,115 For example, in 
decabrominated BDE-209, ΔEZPE for XB interactions at all sites is favorable by more than -26.00 kcal 
mol-1 in agreement with a study showing debromination at each site.115 However, its C-Br bonds are less 
activated than expected compared to the penta- and hexabrominated compounds, considering its more 
favorable ΔEZPE. This discrepancy is the result of the C-Br* character being delocalized over all C-Br 
bonds in the LUMO. In addition, a study of THRβ (which is involved in binding T3) showed that 
increasingly brominated PBDEs/OH-BDEs caused a steady increase in overall inhibition, a trend similar 




Figure 13. Comparison of the activation of C-Br with respect to ΔEZPE in the PBDEs/OH-BDEs by A) 
XB location; B) degree of bromination. 
 
 
The addition of hydroxyl groups to OH-BDEs may enhance their affinity for Dio. XB strength 
and activation of C-Br bond for OH-BDEs varies depending on the proximity of the hydroxyl group to the 
site of XB and the identity of the compound. An adjacent hydroxyl group can stabilize the XB 
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interactions on some of the PBDEs/OH-BDEs (Figure 14). For example, XB at the para position of OH-
BDE-154 has a more favorable interaction (XB-p-OH-BDE-154: ΔEZPE=-23.90 kcal mol-1) than at the 
meta position (XB-m-OH-BDE-154: ΔEZPE = -19.79 kcal mol-1) even though interactions to para XB are 
generally weak. Additionally, both XB-p-5a-OH-BDE-99 and XB-p-6a-OH-BDE-99 have hydroxyl 
groups on the same ring as the para-XB interaction, but in the former molecule, the adjacent hydroxyl 
group activates the C-Br more (+0.122 Å vs. +0.105 Å) near the hydroxyl group (Figure 14). However, 
XB-p-6a-OH-BDE-99 has a more favorable XB interaction (ΔEZPE = -17.97 kcal mol-1) than XB-p-5a-
OH-BDE-99 (ΔEZPE = -15.65 kcal mol-1). Despite XB-p-5a-OH-BDE-99 having a neighboring OH group 
to the XB site, the DFT optimized structure has the OH proton facing away, preventing stabilization of 
the partial charge of the carbon within the C-Br bond, leading to a less favorable XB interaction.  4-OH-
BDE-90 appears to follow the opposite trend: its most favorable interaction is next to a hydroxyl group 
(XB-m-4-OH-BDE-90, with ΔEZPE = -24.67 kcal mol-1) however activation of C-Br is highest at XB-o-4-
OH-BDE-90 (+0.197 Å). In contrast for 3-OH-BDE-47, the most favorable XB reaction occurs adjacent 
to the hydroxyl group and activates the C-Br bond the most (ΔEZPE = -22.63 kcal mol-1, Δd(C-Br) = 
+0.167 Å). In general, the most favorable interactions in these compounds may result from interactions to 
a halogen adjacent to a hydroxyl group flanked by another halogen. Similarly, interactions with OH-
BDEs were favored when the hydroxyl group was nested between two bromine groups in in silico 
sulfotransferase docking simulations of SULT1A1. OH-BDEs may have adopted this pattern to mimic the 
structure of TH substrates, which could explain the higher levels of toxicity and stronger XBs relative to 





Figure 14. DFT optimized structures of selected compounds, with their corresponding ΔEZPE values. 
 
 
The trends found for PBDEs are consistent with experimental observations of inhibition of TH 
pathways by Roberts et al.,45 who compared the inhibition of Dio2 with several PBDEs and OH-BDEs. 
For these compounds, there is no noticeable effect on deiodination of T4 at the low-nM range expected 
physiologically for BDE-99 and 5’-OH-BDE-99. Significantly higher concentrations (1000-5000 nM) 
were needed for Dio2 inhibition as the brominated compounds have less favorable XB interactions 
compared to the THs. 3-OH-BDE-47 (4 Brs, ΔEZPE = -22.63 kcal mol-1) was the best inhibitor and the 
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only OH-BDE that exhibits short-term inhibition (1 hr) at a reasonably low concentration (1000 nM). 
Neither BDE-47 (4 Brs, ΔEZPE = -17.54 kcal mol-1) nor 6-OH-BDE-47 (4 Brs, ΔEZPE = -17.57 kcal mol-1) 
were suitable inhibitors of Dio2. Neither compound exhibited inhibition shorter than 6 hours, and 6-OH-
BDE-47 exhibited only slight inhibition (approximately 20%) at 5000 nM after 12 hours. However, 6-
OH-BDE-47 inhibits transthyretin (TTR) a known TH transport protein. This suggests that different 
substitutions will be effective in inhibiting different pathways.116 Our results are comparable with the 
findings of Roberts et al., as each of the PBDEs/OH-BDEs used in their Dio inhibition study were 
modelled by us in the small DFT models. In DFT, the XB interaction for 3-OH-BDE-47 was more 
favorable than the other compounds by ~5 kcal mol-1. Despite the higher level of bromination of 5’-OH-
BDE-99 (5 Brs) which is more effective at inhibiting Dio1,117,118 the structural similarity of 3-OH-BDE-
47 to TH derivatives may contribute to its favorable XB interaction with Dio2. In addition, these results 
suggest that either the threshold that separates XB interaction from nucleophilic dehalogenation is not 
exceeded (i.e. ΔEZPE values from the set of OH-BDEs from Roberts et al.45 are less than -23 kcal mol-1) 
with this set of OH-BDEs or that deiodination is governed by other interactions with the Dio active site.  
2.3 Conclusions 
Modeling of XB interactions of THs, contrast agents and PBDEs using DFT provides insight into 
the competitive inhibition of TH processes by xenobiotics and how they may disrupt thyroid pathways.  
In comparison to THs, PBDEs and OH-BDEs form less favorable XB interactions with MeSe-, both in 
terms of their interaction energies and the activation of the C-Br bond, suggesting that PBDEs/OH-BDEs 
may competitively bind to the active site to prevent the THs from being deiodinated. Overall, XB 
interactions tend to be most favorable at the ortho and meta positions relative to the ether group, and 
weaker at the para position. The lower affinity at the para position may shed light on why THs are only 
ortho- and meta- substituted suggesting a structure-activity relationship that may be targeted for drug 
design. Substitution of additional electron withdrawing groups in both THs and PBDEs enhance XB 
interactions due to stabilization of the LUMO. The fact that weakly interacting TH derivatives also do not 
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undergo deiodination may suggest a threshold for the Se—X interaction strength that must be exceeded to 
convert the XB interaction to a nucleophilic attack. Interactions with the residues surrounding the 
selenocysteine (Sec170) of Dio will also be a factor in the ability of THs and PBDEs/OH-BDEs to 
interact with and either undergo dehalogenation or block the active site. Full modeling of XB interactions 
to the active site of Dio are underway to determine the role of active site residues in selectivity.  
2.4 Computational Methods 
DFT optimized geometries of the selected compounds were calculated using Gaussian 0957 using 
the hybrid exchange correlation functional mPW1PW91119 paired with a triple-ξ basis set for the heavy 
atoms (TZVP).120 The relativistic effective core potential basis sets of Hurley et. al.121 and Wadt and 
Hay122 were used for selenium and the halogens, respectively, and augmented with polarization and 
diffuse functions. Optimized structures were confirmed as minima on the potential energy surface by 
inspection of their vibrational frequencies. Donor-acceptor interactions were calculated using NBO 3.055 












CHAPTER 3  
HALOGEN BONDING INTERACTIONS OF POLYCHLORINATED BIPHENYLS AND THE 
POTENTIAL FOR THYROID DISRUPTIONb 
 
3.1 Introduction 
Polychlorinated biphenyls (PCBs) are a class of industrial flame retardants with high chemical 
stability.123,124 Runoff of these persistent organic pollutants is of concern because they do not readily 
breakdown in the environment and bioaccumulate in various organisms.124–126 Pollution by microplastics 
may contribute to contamination by PCBs and other organohalogen compounds.127,128 PCBs are well-
known endocrine disruptors that may interfere with thyroid hormone (TH) homeostasis.129–132 Exposure to 
PCBs can cause negative long-term neurodevelopmental effects and cognitive deficits,133–135 including 
lower motor activity,136–138 autism,139,140 and ADHD.141,142 Although many formulations of PCBs ceased 
production in the late 1970s, they still contaminate many urban areas.143–146  
PCBs are classified as dioxin-like (no ortho chlorines) or non-dioxin-like (one or more ortho 
chlorines) (Figure 15).147–149 The former have been considered structurally similar to the toxic 
polychlorinated dibenzodioxins (PCDDs, i.e. 2,3,7,8-tetrachlorodibenzodioxin (TCDD), Figure 15), 
which are agonists to the aryl hydrocarbon receptor (AhR).150 Non-dioxin-like PCBs (one or more ortho 
chlorine), on the other hand, are neurotoxic at much higher concentrations151 and inhibit transthyretin 
(TTR), a transport protein for thyroid hormones.152 PCBs do not readily inhibit thsyroxine-binding 
globulin (TBG), but certain hydroxylated PCBs (OH-PCBs) have strong affinities for both TTR and 
TBG153–155 and inhibit TH sulfation.156,157  
                                                           




Figure 15. Selected sample structures of PCBs and TCDD. 
 
 
Iodothyronine deiodinases (Dio) are thioredoxin-fold selenoproteins that regulate TH 
homeostasis.2,5,78,158 For example, deiodination of the prohormone thyroxine (T4) to triiodothyronine (T3) 
is an activating pathway. Disruption of thyroid hormone homeostasis leads to side effects including 
hypothyroidism, cardiovascular disease, and structural abnormalities.39,82,86 Dio proteins play an important 
role in early developmental stages108 and a recent study suggests that PCBs may inhibit their activity in 
infants.159 PCBs, dioxins and other organochlorine compounds have also been shown to inhibit Dio in 
various organisms, such as rats,43,160,161 fish,162 birds,163 chickens,164,165 and eels.166 However, other studies 
show inconsistent relationships between organochlorine levels and Dio activity.44,160,167–171 
Deiodination is facilitated by a conserved selenocysteine (Sec) residue at the Dio active site.35 
Bayse et. al37 have linked halogen bonding (XB) to the deiodination mechanism of THs with support from 
other groups through experimental studies using Dio mimics,172,173 computational modeling and the X-ray 
structure of Dio3 catalytic region.35 XB interactions have numerous applications to drug design and 
crystal engineering103,174–176 and are often described as an electrostatic interaction with a “σ-hole” along 
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the bond axis of the halogen.102,104,177,178 However, several authors have noted that this popular model de-
emphasizes significant contributions such as covalency and dispersion to the XB interaction.179–187 
Alternatively, XB can be described as the donation of electron density from the lone pair of a donor (such 
as S or Se) to the antibonding σR-X* orbital (where X = I, Br, or Cl) of the acceptor (Figure 
16).37,39,105,106,179,188,189 Overall strength of the XB donor-acceptor interaction (ΔED→A) is inversely related 
to the strength of the C-X bond, due to the lower lying σR-X* orbitals of weaker bonds, such as those in 




Figure 16. XB interactions as described by the molecular orbital model. 
 
 
XB has been proposed as a possible means of inhibition of Dio activity by halogenated organic 
compounds.39,179 PCBs, for example, could block deiodination through an XB interaction with the 
selenium center of the active site Sec. In a previous study, we compared the strength of XB interactions 
between a small model of the Dio active site (SeMe-) and a series of THs and potential organohalogen 
inhibitors: polybrominated diphenyl ethers (PBDEs) and their hydroxylated metabolites (OH-BDEs).39 
The iodinated THs had stronger XB interactions than the PBDEs by approximately 10 kcal mol-1, 
consistent with more favorable XB interactions in larger halogens (I > Br > Cl).104 In this study, trends in 
the strength of Cl—Se interactions with the SeMe- model of Dio are examined using density functional 
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theory (DFT) in terms of the potential for PCBs to inhibit Dio mediation of TH homeostasis. 
Additionally, the conformational flexibility of PCBs is discussed in terms of the inhibition of a wider 
range of TH-related proteins. Both the XB interaction strength and the ability of the PCB to adapt to the 
protein active site are likely key factors in the toxicity of individual compounds. 
3.2 Results and Discussion 
Cl—Se XB interactions with SeMe- were modelled at the DFT(M06-2X)/TZVP+ level for all 209 
possible PCB congeners at each unique ring position (ortho, meta, para) to examine trends in terms of 
Natural Bond Orbital (NBO) donor-acceptor energies (ΔED→A)55 and zero-point energy corrected 
interaction energies (ΔEZPE=EZPE(MeSe-(PCB))-EZPE(MeSe-)-EZPE(PCB)) (Appendix B and C). XB 
complexes are labeled according to the position where XB takes place (i.e. 2, 2’, etc.). For example, XB-
3-PCB-77 designates the complex with the XB interaction at the 3-position on PCB-77 (3,3’,4,4’-Cl). 
PCBs generally have weaker X—Se interactions (ΔEZPE = -1.0 - -16.0 kcal mol-1) compared to 
PBDEs (ΔEZPE = -11.5 - -28.2 kcal mol-1) and THs (ΔEZPE = -21.0 - -33.0 kcal mol-1),39 consistent with 
less favorable XB with decreasing size of the halogen. Similar to PBDEs and THs, the interaction strength 
increases with increased chlorination of the PCB (i.e. ΔEZPE = -2.28 kcal mol-1 for XB-4-PCB-3, ΔEZPE = 
-11.62 kcal mol-1 for XB-2-PCB-209 (2,2’,3,3’,4,4’,5,5’,6,6’-Cl).) Based upon the lack of deiodination 
for 3-T1,39 which has the weakest XB interaction (ΔEZPE = -21.42 kcal mol-1)39 of the series of THs, we 
have proposed that the strength of the XB interaction must exceed a threshold in order for nucleophilic 
dehalogenation to be favorable.39 Because the aryl chlorides’ XB interaction strengths are generally lower 
than the THs, PCBs are unlikely to meet the energy threshold required to undergo dehalogenation, and 
instead reversibly bind to the active site to block TH activation. 
Overlap between the Se lone pair and the high energy C-Cl* orbital is less favorable than 
donation to the lower energy C-Br* and C-I* orbitals (average εLUMO ≈ 1.5241 eV for PCBs, -1.0882 eV 
for PBDEs, -1.9054 eV for THs).39 Reduced donation of the Se lp orbital into the C-Cl* orbital fragment 
leads to smaller donor-acceptor energies (ΔED→A ranges from 1.0 to 10.0 kcal mol-1 for PCBs (Figure 17) 
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vs. 20.0-50.0 kcal mol-1 for PBDEs and 40.0-55.0 kcal mol-1 for THs).39 Similar to results for PBDEs,39 
the higher-substituted PCBs exhibit shorter Cl—Se distances and increased donation from the Se lp 
fragment (Figure 17). However, because C-Cl bonds are weak XB partners, Cl—Se distances in PCBs are 
generally longer than Br—Se distances observed for PBDEs and I—Se interactions of THs (average 




Figure 17. Comparison of donor-acceptor energies vs. d(C-Cl) by A) XB position and B) degree of 
bromination and donor-acceptor energy and donor-acceptor energies vs. d(Cl-Se) by C) XB position and 
D) degree of bromination. 
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The donation of electron density into the R-X* MO in an XB interaction lengthens and activates 
the R-X bond for nucleophilic attack in proportion to the strength of the XB interaction. Average XB 
interaction strengths correlate with the weak activation of the C-Cl bond (Δd(C-Cl)= +0.003 Å, ΔED→A = 
7.35 kcal mol-1, Figures 17 and 18A) compared to the PBDEs (Δd(C-Br)= +0.150 Å, ΔED→A = 39.14 kcal 
mol-1) and THs (Δd(C-I)= +0.177 Å, ΔED→A = 47.49 kcal mol-1).39 d(C-Cl) and d(Cl-Se) appear to be 
independent of XB position, but increased halogenation generally leads to increased C-Cl bond lengths 
(Figure 17). For example, XB to PCB-205 (8 Cls) has a greater activation of C-Cl than to PCB-61 (4 Cls) 




Figure 18. Comparison of zero-point energy corrected interaction energies (ΔEZPE) to A) the activation of 
the C-Cl bond (Δd(C-Cl)) by XB position; B) percent contribution of X (%X) by XB position. 
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NBO analysis was used to determine the weighting of σR-X* towards X (%X). %X measures the 
donation of X into the C-X σ* antibonding orbital, which enhances overlap with the donor lone pair. 
Therefore, a higher %X should correspond to a stronger XB interaction.179  The stronger XB interactions 
of brominated and iodinated aromatics correlate with the higher contribution of X to the σR-X*-type MOs 
(%X for aryl bromides = 50-55%; for aryl iodides = 55-65%).179 In contrast, %X for PCBs range from 
approximately 45% to 48% (Appendix C), similar to other aryl chlorides (%X = 40-50%).179 Additionally, 
although the acceptor σR-X* MO is generally the LUMO of heavier aryl halides, PCBs tend to have 




Figure 19. XB interactions at both the meta and para positions respectively, along with the LUMO 





Cl—Se XB interactions are strengthened by the electron-withdrawing effect of the neighboring 
chlorines which stabilize σR-X* and increase their %X contribution.179 The largest ΔED→A are found for 
meta and para XB complexes that interact through a chlorine flanked by two other chlorines. The weaker 
donor-acceptor energies at the ortho position resulted in a number of cases where the interaction was so 
weak that no stable XB complexes could be found. In contrast, PBDEs have their largest ΔED→A values 
primarily for ortho and meta XB interactions.39 In terms of the interaction energy ΔEZPE, electrostatic 
interactions with the adjacent ring lead to slightly more favorable XB interactions at ortho positions (-
7.62 kcal mol-1) on average compared to meta and para (-6.84 and -7.01 kcal mol-1 respectively). ΔEZPE 
(Figure 18B) for meta and para XB interactions to chlorines with two adjacent halogens cluster at higher 
%X (average %X = 47.6 ± 0.3%) and shift toward lower overall ΔEZPE than PCBs with one (middle 
cluster, average %X = 46.8 ± 0.3% across all PCBs) or no neighboring halogens (leftmost cluster, average 
%X = 45.9 ± 0.4% (ortho) and 45.8 ± 0.4% (meta and para) respectively, Figure 18).   
Experimental data on the disruption of Dio activity by PCBs is limited.159,190,191 Coimbra et al. 
assessed Dio activity in tilapia upon exposure to Aroclor 1254, an industrial mixture containing PCB-77 
(ΔED→A = 4.49 and 5.28 for meta and para positions respectively). Dio3 activity increased in the brain 
over the course of 3 and 5 weeks, while hepatic Dio1 and brain Dio2 activity decreased.191 Exposure to 
Aroclor 1254 caused an increase in plasma TH levels, which could be indicative of Dio inhibition. In a 
similar study, Morse et al. found that neither PCB-77 nor Aroclor 1254 had an effect on brain Dio2 
activity in adult mice.190 Analysis of a select group of PCBs on deiodinase activity in the cord blood in 
infants found a positive correlation between 2,4,5-substituted PCBs 118 (2,3’,4,4’,5-Cl), 138 
(2,2’,3,4,4’,5’-Cl), 146 (2,2’,3,4’,5,5’-Cl), 153 (2,2’,4,4’,5,5’-Cl), 183 (2,2’,3,4,4’,5’,6-Cl), and 187 
(2,2’,3,4’,5,5’,6) concentrations and the T3/rT3 ratio, suggesting a negative effect on Dio3 activity159 
consistent with stronger interactions to highly-halogenated PCBs (≥ 5 Cl). The C-Cl bond is most 
activated at the meta position of the 2,4,5 ring of PCB-118 and PCB-153 (ΔED→A = 5.24 kcal mol-1 and 
5.57 kcal mol-1) while the most activated C-Cl bond for PCB-138 and PCB-183 is located at the meta 
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position opposite the 2,4,5 ring (ΔED→A = 6.62 kcal mol-1 and 7.27 kcal mol-1). Finally, the ortho C-Cl 
bonds opposite of the 2,4,5 ring in PCB-146 and PCB-187 are the most activated (ΔED→A = 5.51 kcal mol-
1 and 6.21 kcal mol-1).     
The position dependence of the XB donor-acceptor strengths suggests that PCBs with substitution 
patterns similar to the preferred TH substrate for a Dio paralog192 may more effectively inhibit that Dio 
type. For example, Dio1 can deiodinate both inner and outer rings and has a high affinity for rT3, while 
Dio2 and Dio3 are specific to outer ring deiodination (ORD, or meta-deiodination) and inner ring 
deiodination (IRD, or ortho-deiodination) and prefer T4 and T3 respectively (Figure 20). A PCB like PCB-
80 (3,3’,5,5’-Cl) with key interactions at a meta chlorine (ΔED→A = 4.42 kcal mol-1) may display better 
inhibition towards Dio2 (Figure 20).192 Likewise, a PCB like PCB-54 (2,2’,6,6’-Cl) which interacts only 
at an ortho chlorine (ΔED→A = 3.62 kcal mol-1) may suggest better inhibition towards Dio3 (Figure 20). A 
PCB like PCB-155 (2,2’,4,4’,6,6’-Cl) is most activated at the ortho position compared to the para 
position (ΔED→A = 5.38 vs. 4.96 kcal mol-1) and may preferentially target Dio3. A PCB like PCB-136 
(2,2’,3,3’,6,6’-Cl) is more activated at 6-Cl (ΔED→A = 4.63 kcal mol-1, ortho) than at 3-Cl (ΔED→A = 3.62 
kcal mol-1, meta) may also favor inhibition of Dio3. PCBs that display both ortho and meta chlorines but 
have the highest activation of C-Cl at the para position (i.e., PCB-128 (2,2’,3,3’,4,4’-Cl) (ΔED→A = 6.72 













































Figure 20. Pathways of TH inner ring and outer ring deiodination (IRD, ORD) and their byproducts, with 
PCBs that may specifically target Dio2 (PCB-80) and Dio3 (PCB-54) respectively. 
 
 
While the ΔEZPE and ΔED→A energies provide insight to the favorability of XB interactions with 
PCBs, many proteins require ligands to bind in a certain conformation for substrate recognition.193,194 For 
example, different TH orientations were found within the active site(s) of TH-binding proteins from the 
crystallographic data obtained from the Protein Data Bank.195 The large iodine atoms of THs cause some 
conformations to become unfavorable due to steric clashes with residues on the surface of proteins.195,196 
PCBs have been incorrectly assumed to have a coplanar structure (i.e., with an inter-ring dihedral of θ = 
0°) in analogy to the structure of TCDD. However, the optimized geometries of all PCBs are nonplanar197 
and X-ray crystal structures of TTR-PCB complexes show that the PCBs are not coplanar within the 
binding pocket (PDB IDs: 2G5U, 2G9K, 2GAB).198 At the coplanar orientation (θ = 0°), delocalization of 
the biphenyl π-electrons is maximized, but sterics between the ortho positions on the opposing rings 
contributes to a large barrier for twisting through this conformation.199 In contrast, when the rings are 
39 
 
perpendicular (θ = 90°), steric interactions are minimized, but there is no delocalization between the 
phenyl rings. The slightly twisted structure of the unsubstituted biphenyl with two minima at θ = 40° and 
θ = 140°, separated by a larger barrier at 0° and a small one at θ = 90°, represents a balance between these 
steric and electronic factors (Figure 19).199–201 The non-ortho PCBs have been shown to have a lower 
twist barrier at θ = 0° and a higher twist barrier at θ = 90° in the presence of explicit water.197 The 2,2‘-
PCBs have their lowest energy structure near θ = 80° where steric clashes between Cls on opposite rings 
is minimized (Figure 21). As the ortho positions become halogenated, the minima shift closer to θ = 90° 
up to 2,2‘,6,6‘-ortho PCBs which has a single minimum. Increased ortho-substitution also results in 
higher and steeper barriers for twisting through the coplanar conformation leading to less flexibility about 









Previous studies proposed a “buttressing” effect, where adding meta chlorines to ortho-
chlorinated PCBs showed that the barrier for forcing coplanarity was increased, but only in cases where 
the meta addition is adjacent to an ortho chlorine.202–204 The adjacent meta Cl repels the ortho Cl, forcing 
it out of the plane of the ring. The PES curves of PCB-10 (2,2’-Cl), PCB-24 (2,3,6-Cl), and PCB-27 
(2,3’,6-Cl) show the effect on the barrier for twisting at θ = 0° only increases by approximately 1.0 kcal 
mol-1.199,204 While some highly ortho-chlorinated PCBs like PCB-204 (2,2’,3,4,4’,5,6,6’-Cl, ΔED→A = 6.04 
kcal mol-1) and PCB-209 (2,2’,3,3’,4,4’,5,5’,6,6’-Cl, ΔED→A = 7.94 kcal mol-1) have favorable XB 
interactions, the inflexibility of these compounds due to steric hinderance of the ortho chlorines may 
reduce their ability to bind to Dio or other TH-related proteins.  
PCBs have been shown to disrupt other pathways, such as displacement of THs from transport 
proteins (i.e. TTR)94,205 and inhibition of the sodium-iodide symporter (NIS),206–208 which may account for 
the increase of THs in plasma. Chauhan et al.138 determined the trends in the inhibition of a transport 
protein TTR for a series of PCBs. For PCBs without ortho chlorides, competitive binding to TTR for 
lightly chlorinated species is strongest in the order of PCB-38 (3,4,5-Cl) > PCB-14 (3,5-Cl) > PCB-39 
(3,4’,5-Cl) > PCB-35 (3,3’,4-Cl) > PCB-11 (3,3’-Cl) > PCB-37 (3,4,4’-Cl) = PCB-15 (4,4’-Cl). Heavily 
chlorinated PCBs (≥ 4 Cl) inhibit TTR binding in the order of PCB-127 (3,3’,4,5,5’-Cl) > PCB-80 
(3,3’,5,5’-Cl) > PCB-126 (3,3’,4,4’,5-Cl) > PCB-77 (3,3’,4,4’-Cl). Although the Cl—Se XB interactions 
with the SeMe- Dio model are stronger than any XB interactions found with the TTR binding site,209 the 
trends in XB strength should be similar. The trend within the lightly and heavily chlorinated PCBs track 
closely with the ability to inhibit TTR. For example, PCB-38 had the most favorable Cl—Se interaction 
(ΔED→A = 6.22 kcal mol-1) while PCB-11 had the least favorable interaction (ΔED→A = 2.06 kcal mol-1) of 
the lightly chlorinated series. PCB-127 contains the most favorable XB interaction (ΔED→A = 6.50 kcal 
mol-1) and PCB-77 has the least favorable interaction (ΔED→A = 2.20 kcal mol-1) for the most substituted 
series. Generally, para (4,4’) PCBs had very low affinity for TTR, with the exception of highly 
substituted PCB-169 (3,3’,4,4’,5,5’-Cl),138 despite the possibility of favorable XB interactions. For 
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example, PCB-126 is almost equal to PCB-127 (ΔED→A = 6.43 kcal mol-1 vs 6.50 kcal mol-1), but its TTR 
inhibition is over two orders of magnitude smaller. Substitution at both para positions may have a steric 
effect not reflected in our small model that prevents PCBs from accessing the TTR binding site.  
In the ortho-only substituted PCBs, the order of inhibition strength towards TTR was PCB-19 
(2,2’,6-Cl) > PCB-4 (2,2’-Cl) = PCB-10 (2,6-Cl) >> PCB-1 (2-Cl) = PCB-54 (2,2’,6,6’-Cl). Although the 
XB strengths for this series are comparable to the non-ortho PCBs, their activity is more than two orders 
of magnitude lower than the non-ortho PCBs due to the reduced flexibility of the ortho PCBs. The most 
substituted of this series, PCB-19 and PCB-54, have similar Cl—Se interactions (ΔED→A = 3.90 and 3.62 
kcal mol-1, respectively), but PCB-19 is better able to inhibit TTR given its limited conformational 
flexibility relative to the more rigid PCB-54 (Figure 19). Overall, the inflexibility of ortho-substituted 
PCBs despite having potential XB interactions of similar strength to non-ortho PCBs could explain their 
lower toxicity.  
3.3 Conclusions 
Understanding the PCB interactions within the endocrine system could have significant 
pharmacological implications, such as the design of mimics that target TH-binding proteins. Modelling 
the Cl—Se XB interaction between the SeMe- model and PCBs provides insight on the potential 
inhibition of the iodothyronine deiodinases through competitive active site binding. PCBs have less 
favorable interactions than THs or organobromine PBDE inhibitors, in agreement with XB dependence on 
the size of the halogen (I > Br > Cl). PCBs would be unlikely to meet the proposed energy threshold for 
dehalogenation and would inhibit Dio by blocking the active site through a Cl—Se interaction. Meta and 
para XB donor-acceptor interactions are generally more favorable than ortho-XB interactions in PCBs, 
since these XB interactions can contain more than one adjacent Cl. In these cases, the electron 
withdrawing adjacent Cls stabilize the R-Cl* acceptor MO and increases the %X contribution for 
improved overlap with the SeMe- donor. PCBs may target different Dios depending on the donor-acceptor 
energies of the XB interactions. For example, PCBs with strong meta-XB interactions may prefer Dio2 
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inhibition, while those with strong ortho-XB interactions may prefer Dio3 inhibition. As PCBs become 
more ortho-halogenated, the twisting energy barrier around the C-C biphenyl bond increases, limiting 
flexibility and preventing some conformations from being readily accessible, suggesting the ability to 
adapt to the binding site may be important for inhibition of Dio and other thyroid hormone related 
proteins.  
3.4 Computational Methods 
Gaussian0957 was used to calculate the DFT optimized geometries of the PCBs and the XB 
complexes with SeMe- using the M06-2X exchange-correlation functional104 with a triple-ζ basis set for 
heavy atoms (TZVP). The relativistic core potential basis sets of Wadt and Hay was used for selenium 
atoms and augmented with polarization and diffuse functions.122 Inspection of vibrational frequencies 
confirmed that optimized geometries were true minima. Donor-acceptor interaction energies ΔED→A were 
determined by second-order perturbation theory as the stabilization of a filled σ-type orbital by the 
interaction with an empty σ*-type orbital. as described by Reed et al.55 ΔED→A values were calculated 












CHAPTER 4  




Iodothyronine deiodinases (Dios) are selenoproteins containing a rare selenocysteine residue 
involved in catalytic deiodination.35,210–213 Dios adopt a thioredoxin-fold, containing five β-strands flanked 
by four α-helices.214–218 Unlike other Trx proteins, which contain a CXXC motif in the active site, Dios 
incorporate a SCTU sequence (U = Sec). Three classes have been studied (Dio1, Dio2, Dio3), with each 
involved in regioselective deiodination of THs.78,79,219–223 Dio2 and Dio3 are specific to outer ring 
deiodination (ORD) and inner ring deiodination (IRD) respectively, while Dio1 can perform both. 
Because of the regiospecificity of each Dio, they play different roles to maintain TH homeostasis. For 
example, ORD by Dio2 is essential for activating thyroid hormones to T3, while IRD by Dio3 produces 
rT3, an inactive TH metabolite. Deiodinase activity can be inhibited by endocrine disrupting chemicals 
(EDCs) such as polybrominated diphenyl ethers (PBDEs), polychlorinated biphenyls (PCBs), 
dibenzodioxins, iodoacetic acid (IAc), and gold thioglucose (GTG).39,40,150,224,225  
 The crystal structure of the Dio3 catalytic domain (PDB = 4TR4) was isolated by Schweizer et 
al.35 The active site containing the Sec residue is overlooked by a flexible D-loop. The loop is on the 
surface of the protein and contains roughly 20 residues.35 This irregular secondary structure has been 
classified as an Ω-loop, which was first described by Fetrow et al.226 Ω-loops are found almost 
exclusively on protein surfaces and serve either a structural or catalytic role within the protein. For 
example, point mutations within the Ω-loop of β-lactamase show a decrease in catalytic activity.227 The 
proximity of the Ω-loop to the active site in Dio3 suggests it has a possible role in substrate binding and 
catalytic deiodination.36 During a 20 µs MD simulation, multiple stable conformations of the Ω-loop were 
observed, with the most stable conformation (C) exposing a cleft in the active site where T4 can bind.36 
AutoDock was used to dock the T4 substrate within the cleft of this conformation. The bonding, 
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nonbonding, and charge parameters of the I—Se XB interaction between the T4 iodine and Sec selenium 
were derived from a previous study.228  A “dummy atom” approach accounted for the σ-holes on iodines 
not directly involved in the XB interaction.228 A 4.0 μs MD simulation of the Dio3(C)-T4 complex shows 
that the protein is stable and an ancillary outer ring XB interaction forms to a carboxylate oxygen of 
Asp211 within the Ω-loop.36 
Currently, no structural data regarding a dimeric form of Dio3, which is the active form of the 
protein. An experimental study suggests Dio3 is catalytically active only as a homodimer.46 Obtaining 
crystal structures of membrane-bound proteins is challenging.229 Predicting these interactions 
automatically using high accuracy in silico methods level is computationally expensive for large 
systems.230 Numerous protein-protein docking websites have been developed over the past 30 years, such 
as ClusPro, ZDOCK, and ATTRACT, with each differing in the algorithm used for searching the six-
dimensional transformation space.231–233 There are conflicting viewpoints regarding the location of the 
dimerization interface of Dio3. Sagar et al. suggests dimerization occurs at a large interfacial region that 
includes the top of two β-strands that make up an elongated β-sheet within the Ω-loop similar to the 
canonical β1α2β2 motif in thioredoxin (Figure 22A).46,47 Because of the high level of sequence similarity 
around the β1α2β2 motif to that of oxidized human thioredoxin (PDB = 1ERU), a Dio model was 
superimposed onto the crystal structure of human thioredoxin.47 On the other hand, Schweizer et al. 
postulates that Dio3 dimerizes along the α3β4 interface.35 In mammalian 2-Cys peroxiredoxin (HBP23, 
PDB = 1QQ2), the α3β4 region mediates dimerization (Figure 22B).234 The α3β4 region shares high 
sequence similarity to the same domain in Dio3, and as such the Dio interface proposed by Schweizer was 
fitted onto that of HBP23.  
In the present study, we compare the structure and sequence of Dio3 to other known thioredoxin-
fold proteins to gain insight into the conflicting hypotheses regarding Dio3 dimerization. After 
determining the probable dimer interface of Dio3, a homodimer was constructed and refined using in 
silico databases SymmDock and GalaxyRefineComplex. The refined symmetric dimer was subject to MD 
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simulations to test for dimer stability. Hydrogen bonding analysis and MMGBSA calculations were 





Figure 22. Template structures used as the basis for describing Dio3 dimerization. A) Human thioredoxin 
(PDB = 1ERU); B) HBP23 (PDB = 1QQ2). The regions involved in dimerization interactions in each 
protein are shown in opaque. 
 
 
4.2 Results and Discussion 
 The structures of Dios are comparable to other proteins, such as glutaredoxins (Grxs), protein 
disulfide bond isomerases, and peroxiredoxins (Prxs), as they contain a thioredoxin-fold.235 Prxs are 
proteins that serve as antioxidant proteins by reducing reactive oxygen and nitrogen species.236,237 Most 
proteins in this subfamily have two conserved Cys residues (2-Cys): a peroxidatic cysteine (CP) and a 
resolving cysteine (CR). The CP is located at the second cysteine of the universal thioredoxin CXXC motif 
and is directly involved in reducing peroxide substrates.238 The CR is typically located in the C-terminal 
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helix of peroxiredoxins and forms an inter-subunit disulfide bond to CP.236 The oligomeric state of 
peroxiredoxins changes depending on whether the protein is reduced or oxidized. In the reduced form, 
peroxiredoxins form (α2)5 decamer structures such as the structure of plasmodium vivax Prx1a (PDB = 
4L0U, Figure 23).239 In the oxidized form, peroxiredoxins dissociate to from the decameric form to 
produce dimeric structures. Dissociation can occur at either the B-interface or the A-interface of 
decamers, which produces either A-type or B-type dimers respectively.240 A-type (or “alternate”) dimers 
are formed primarily by interactions at the β1α1 turn, an αD region, and a variable double β-sheet sequence 
region, while B-type (for β-strand) dimers consist of interactions of α3 and β4 (Figure 23).236 
Peroxiredoxins are further classified into different subfamilies (Prx1, Prx5, Prx6, Tpx) with each 
preferring different types of dimerization. For example, Prx5 and Tpx proteins prefer A-type 




Figure 23. A) Decameric structure of plasmodium vivax Prx1a (PDB = 4L0U); B) close-up of the A-type 




The conflicting viewpoints of proposed dimer interfaces of Dio3 between within the literature 
could be attributed to the observance of different dimerization interfaces in Prxs. To determine which 
description is the most reasonable to describe Dio3 dimerization, sequence alignments of Dio3 (4TR4) vs. 
A-type and B-type dimers was performed using the Clustal-Omega server (Figure 24, 25).241 The regions 
of Dio3 (4TR4) aligns well with both A-type and B-type dimers up through β2, however the variable 




Figure 24. Sequence alignment of Dio3 (4TR4) vs. A-type dimer proteins. The dimer interface residues 
are highlighted in yellow. The locations of the conserved Phe residues in ‘ball-and-socket’ interactions 




Figure 25. Sequence alignment of Dio3 (4TR4) vs. B-type dimer proteins. The dimer interface residues 
are highlighted in yellow. 
 
 
In comparing Dio3 (4TR4) to the other A-type proteins, the sequence identity is very low (around 
10-15%). All A-type dimers but the asymmetric dimer 1TP9 have the β1α1 turn region, the αD region, and 
the variable double-stranded β-sheet region within their dimer interfaces. A-type dimers contain a 
conserved Phe residue at either the β1α1 turn or the region before α2 region forms interdimer “ball-and-
socket” hydrophobic interactions.  “Ball-and-socket” interactions have been observed in other proteins 
such as glutathione peroxidase (Gpx) (PDB = 1GSU) and λ Cro (PDB = 5CRO).239,242,243 In Gpx, Phe56 
forms interdimer hydrophobic interactions with Leu137, Phe140, and Val98, while in λ Cro Phe58 
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interacts with Ala33 and Ile30 on the opposite chain.242,243 In both proteins, mutation of these key Phe 
residues largely destabilize the dimeric state.242,243 The Prx5 proteins (4L0U, 1XIY, 1TP9, and 1OC3) 
each have the conserved ‘ball-and-socket’ Phe residue within the β1α1 turn, while the conserved Phe in 
Tpx proteins (3I43 and 1Q98) is in the region preceding α2 (Figure 24). The interfacial region of 1ERU, 
the template structure used for the dimer description by Sagar et al., does not have a Phe residue at either 
of the A-type interfaces but does contain Trp31 within the β1α1 region in the same position as the 
conserved Phe in Prx5 proteins. Within 1ERU, Trp31 could emulate the A-type dimer ‘ball-and-socket’ 
hydrophobic interactions by interacting with Val71/Met74 on the opposite monomer (Figure 26). 1ERU 
lacks the αD and extended double β-sheet regions of the other A-type dimers and instead has an interfacial 




Figure 26. Structures of comparable ‘ball-and-socket’ interactions within A) 1ERU; B) 1XIY; C) 3I43. 
 
 
Dio3 (4TR4) does not have a Phe at either of the conserved positions in the Prx5 or Tpx proteins 
and instead has Thr and His occupying those spots in the sequence alignments (Figure 24). In Dio3, the 
only Phe located at the surface is Phe258, which shields the substrate in the active site from the solvent.35  
Furthermore, A-type dimerization of Dio3 is improbable from a structural standpoint. By overlaying two 
monomer structures of Dio3 onto a Prx5 protein (1XIY) and a Tpx protein (3I43), it is evident that the 
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sterics of the Ω-loop prohibit dimerization at the β1α1 and αD regions simultaneously (Figure 27). In 
comparing Dio3 to 1ERU, 1ERU has a Cys-Cys disulfide bond at the dimer interface that aids dimer 
stability, which Dio3 does not contain. Previous studies that have examined amino acid propensities 
within protein structures also do not support the A-type dimerization description of Dio3. A recent study 
evaluated the propensities of amino acids to occur at dimer interface regions and have found Arg, Tyr, 
and Trp to be the most common residues in these regions and are considered ‘hotspots’ in Ala-scanning 
experiments.244 The Tyr and Trp residues are typically found more towards the center of dimer interfaces, 
which would not be the case if it is assumed Dio dimerizes in a A-type fashion.244 In addition, most of the 
residues within the Ω-loop of Dio3 that make up the proposed β-sheets according to Sagar et al. are 
residues not typically seen in these secondary structures. Of the residues in the proposed β-sheet region 
(sequence: EAHPSDGWVTT), only His and Trp are commonly found in β-sheets.245 Based upon the 
available sequential and structural data of known A-type dimers and the structure of 1ERU, these 
observations suggest A-type dimerization of Dio3 is unlikely to occur and that 1ERU is not a viable 





Figure 27. Structural overlays of Dio3 monomers (in blue, pink) on top of dimeric structures of A) 1XIY; 
B) 3I43 (in tan). 
 
 
 The sequence identity of Dio3 vs. the B-type dimers is around 15-20%, which is higher than the 
sequence identity of A-type dimers. This level of sequence similarity almost falls in line with the 
established ‘twilight zone’ of 20-25%, suggesting that some of the conserved regions of Dio3 and B-type 
proteins could have evolved from a common ancestral protein.246 The interface of B-type dimers consists 
of residues within β4, α3, and the β4α3 turn, and vary between Dio3 and B-type proteins (Figure 25). A 
conserved Gly-Arg dyad sequence is located within the α3β4-turn with 2-Cys peroxiredoxin proteins, 
2C0D, 1QQ2, and 4KCE (Figure 25). In addition, a conserved Val-X-Glu triad within the 2-Cys 
peroxiredoxins is near the beginning of α3 (Figure 25). Within the 2-Cys peroxiredoxins, this conserved 
Glu residue forms an intradimer hydrogen bond to a conserved Arg residue positioned three residues 
down the sequence in 1QQ2 and 4KCE (Figure 25). In the C-terminus, 1QQ2, 2C0D, and 4L0U all 
contain CR, which aids association into decameric structures in the oxidized state by forming a disulfide 
bond to CP near the A-type interface.236  
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Within Dio3, the slightly shorter β-sheet region of Dio3 is compensated by a more flexible Gly-
rich α3β4-turn. Dio3 shares the conserved Gly-Arg dyad with other B-type proteins, however the dyad is 
in the middle of the turn in Dio3 and followed by another Gly residue (Figure 25). This Arg residue in 
Dio3 is Arg275 and has been proposed to help bind the T4 substrate.35 The Gly-rich turn of Dio3 may be 
necessary to allow for more flexibility to accommodate the large T4 substrate. Within α3, Dio3 shares the 
Val-X-Glu triad and an Arg residue in roughly the same position with the 2-Cys peroxiredoxin proteins, 
suggesting Dio3 could display similar stabilizing intramonomer Glu-Arg hydrogen bonding interactions. 
Finally, Dio3 does not have CR in the C-terminal region, suggesting A-type association of dimers to form 
decamers is unlikely to occur. Based upon sequential and structural similarities between Dio3 and B-type 
proteins, we presume Dio3 dimerizes in a B-type fashion and attempt to construct homodimer of Dio3 
based upon the B-type description using protein-protein docking databases. 
Protein-protein docking databases are divided into two main categories, template-based modeling 
and template-free docking.247 In template-based modeling, a protein complex is constructed based on a 
known deposited structure in the Protein Data Bank. Template-based modeling assumes protein-protein 
complexes interact in a similar fashion to known protein structures if the interacting pairs share over 30% 
sequence identity.248 Template-free docking databases uses two stages for structure prediction, a sampling 
stage and a scoring stage. During the sampling stage, thousands of structures are generated and then are 
subsequently scored and ranked based upon known interfacial interactions in other proteins.249 For the 
initial protein-protein docking attempts, monomers of the Dio3 X-ray structure (Dio3(X-ray)) and a 
structure containing a stable Ω-loop conformation (Dio3(C)) that exposes the active site Sec residue were 
submitted to a template-based server (GalaxyGemini) and a template-free server (HawkDock).36 For each 
conformation, GalaxyGemini predicted the same 5 template structures, with only models 3 and 4 
producing dimers (Table 2). The dimer templates are from a thioredoxin-like protein from Aeropyrum 
pernix (3HA9) and a Gpx5 protein (2P5Q), both of which have B-type dimerization (Figure 28). 
HawkDock produced the top ten structures for each conformation based upon MMGBSA energies of the 
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complexes. Although the dimers generated from the Dio3 X-ray structure have lower MMGBSA 
interaction energies compared to Dio3(C), none of these dimers display B-type dimerization and therefore 
were excluded from further analysis (Table 3). From the Dio3(C) structure, only model 6 positions the α3 
and β4 regions at the interface akin to a B-type dimer (Figure 29). Energetic calculations within 
HawkDock show formation of the B-type dimer is favorable (ΔG = -34.65 kcal mol-1, Figure 29, Table 3). 
Although both GalaxyGemini and HawkDock predicted B-type dimers, the produced structures are 
unrefined, as they do not account for optimal interfacial sidechain orientations. In addition, in both 
Dio3(X-ray) and Dio3(C), the β-sheet at the α3β4 interface adopts a crooked conformation. Although there are 
proteins that have interfacial interactions between crooked β-sheets, such as 4HPM and 1Z4E,250 initial 
MD simulations of Dio3(X-ray) and Dio3(C) dimers with interacting crooked β-sheets show these structures 
become unstable quickly. To overcome this issue, the β-sheet within monomeric Dio3 needs to be refined 
before protein-protein docking can be carried out.    
 
 







1 3FKF         4            69.72 
2 3GL3         4            68.81 
3 3HA9         2            65.29 
4 2P5Q         2            67.31 





Figure 28. Structures of the template structures generated using the GalaxyGemini server with the 
structure of Dio3 as the input with templates (A) 3HA9; (B) 2P5Q. 
 
 
Table 3. Binding energies (in kcal mol-1) of the top 10 models of Dio3(X-ray) and Dio3(C) predicted by 
HawkDock. 
   Model Dio3(X-ray)        Dio3(C) 
1 -25.17            -9.45 
2 -33.85           -24.96 
3 -35.65           -26.30 
4 -22.99           -13.42 
5 -53.87           -30.67 
6 -31.00           -34.65 
7 -48.36            -8.52 
8 -20.65           -21.14 
9 -26.48           -27.72 





Figure 29. Structure of the B-type (model 6) dimer generated from Dio3(C) using the HawkDock Server. 
 
 
 An equilibrated Dio3(C)-T4 complex from a previous study was used as the starting structure for 
refinement of the interfacial β-sheet.36 CHIMERA was used to set the dihedral angles of the residues 
within the β-sheet (Thr268 to Gln272) to mimic those commonly found in parallel β-sheets and the 
positions of the β3-β4 turn residues (Ser266 and Gly267) were adjusted slightly (See Methods for 
Details). The refined monomer was then submitted to the SymmDock server to obtain symmetric dimers. 
SymmDock is a free web server that utilizes a geometry-based algorithm to produce symmetric multimers 
with a given order n.230 The details of the files submitted to the SymmDock server are described in the 
Methods section. SymmDock constructed 58 unique symmetric B-type-like dimers. Most of the generated 
models contain structural features that could cause the dimers to destabilize quickly during MD 
simulation. For example, model 2 shows the interfacial β-sheets to be nearly perpendicular to each other, 
which prevents interfacial β-β interactions from occurring (Figure 30A). On the other hand, although 
model 11 has closely interacting antiparallel interfacial β-sheets, the lack of interactions between the α-
helices on the monomers could induce instability (Figure 30B). Of these dimers, only model 16 produced 
a structure that resembled a B-type dimer with a thioredoxin-fold, as it positions the α3β4 regions of the 
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monomers to interact in an anti-parallel fashion (Score = 5750, Figure 30C). Within model 16, close 
contacts exist between the sidechains of the Arg281 residues in the α-helix and the backbone atoms of 
Thr268 and Gly273 (Figure 30D and 30E), which need to be adjusted before an MD simulation can be ran 
on this protein. 
    
 
 
Figure 30. Dimers generated from the SymmDock server. A) Model 2; B) Model 11; C) Model 16. D) 
Close contacts between Arg281 residues between the α-helices in model 16; E) Close contacts between 




 The SymmDock-generated dimer was submitted to GalaxyRefineComplex to reorient the 
sidechains at the interface. GalaxyRefineComplex utilizes a sampling method in which multiple short MD 
simulations are run to allow for repetitive repacking of the side chains within the dimer interface.251 
Comparative studies of models generated by ZDOCK, M-ZDOCK, CAPRI, and CASP experiments show 
the refining process utilized by GalaxyRefineComplex produced the most favorable structures in most 
cases.232,252,253 The refining process emulates protein-protein dimerization by allowing the sidechains 
between the two monomers to dictate inter-protein orientations and intra-protein backbone 
conformations.251 While the other databases listed above can perform repacking of sidechains in interface 
regions, GalaxyRefineComplex is the only web server that allows for symmetric rearrangement of the 
interface while simultaneously reducing close contacts.  
 From the generated SymmDock dimer, GalaxyRefineComplex produced 10 unique structures that 
repack the sidechains within the dimer interface region. The 10 structures were evaluated based upon the 
results of the ligand RMSD (l-RMSD) according to the critical assessment of predicted interactions 
(CAPRI) developed by Lensink et al.; incorrect of l-RMSD > 10 Å, acceptable if l-RMSD = 5-10 Å, 
medium if l-RMSD = 1-5 Å, or high quality if l-RMSD < 1 Å.253 While this assessment has been widely 
accepted as a measure of structure quality, visual inspection of the generated structures is necessary to 
ensure no unfavorable interactions, such as positively-charged sidechains being close together, are 
generated. To narrow down the viable structures, only the high-quality structures were considered 
(models 7, 8, and 10 with l-RMSDs of 0.976, 0.939, and 0.980 respectively, Table 4). The orientations of 
the sidechains at the interfacial α-helices and β-sheet are all highly similar within the three high-quality 
structures (Figure 31). In each structure, Arg291 orients inward and forms a close interaction to the 
carbonyl oxygen of Gln295 on the opposite α-helix (Figure 31A). However, in models 7 and 10, the 
sidechains of Tyr271 of the β-sheet and Trp288 of the α-helix have close contacts between the sidechains, 
whereas the sidechains of Tyr271 and Trp288 in model 8 are orientated to allow for potential π-stacking 
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interactions (Figure 31B). In addition, model 8 has the lowest l-RMSD out all the results and was chosen 
to be subject to MD simulation. 
 
 

















Figure 31. Overlays of the high-quality models generated by GalaxyRefineComplex according to CAPRI. 
The colors red, blue, and green correspond to models 7, 8 and 10 respectively. A) Orientations of the 
sidechains of Arg291 and Gln295; B) Orientations of the sidechains of Tyr271 and Trp288. 
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 A 2 µs MD simulation was run on the constructed dimer. From 0-1 µs, the MD simulation was 
carried out with T4 substrates bound to the active sites. From 1-2 µs, the two T4 substrates were removed 
to verify that the interface maintains its integrity. Energies are calculated using MMGBSA and expressed 
as ΔGholo and ΔGapo for the T4-bound (0-1 μs) and T4-unbound (1-2 μs) parts of the simulation 
respectively. ΔΔG represents the difference in energies between the holo and apo parts of the simulation. 
MMGBSA uses molecular mechanics in tandem with the generalized Born model and the solvent 
accessibility method to predict free energies of a system.254 MMGBSA has been shown to have high 
accuracy in predicting dimerization energies and is able to identify energetic contributions of individual 
residues through decomposition analysis.255,256 MMGBSA interaction energies indicate dimerization of 
Dio3 with T4 bound is favorable (ΔGholo = -38.62 ± 6.81 kcal mol-1) and is further stabilized when the T4 
residues are removed (ΔGapo = -45.67 ± 12.03 kcal mol-1). The time evolution of interaction energies 
shows the electrostatic contributions far outweigh the van der Waals (vdW) interactions within the 
interface region (Figure 32). The trends in interaction energies are consistent with the number of 
hydrogen bonding and hydrophobic interactions, which remain constant in the MD simulation (Figure 
33). Over the course of the 2 µs MD simulation, the protein and its Ω-loops remain stable as evidenced by 
the RMSD plot (Figure 34A). During the first half of the simulation, the T4 residues remain bound to the 
active site and the outer-ring XB interactions to Asp211 in both monomer subunits remain intact. In 
addition, removal of the two T4 substrates at 1 μs slightly destabilizes the protein, as one of the Ω-loops 
deviates from the stable conformation (C) at ~1.5 μs due to the loss of the T4 XB interactions to Asp211 
within the Ω-loop (Figure 34A and 34C).36 Fluctuations within the RMSD plot of the monomer interfaces 









Figure 33. Evolution of interdimer interactions at the Dio3(C) dimer interface region. A) Hydrogen bonds 




Figure 34. Statistical analysis of the MD simulation of the Dio3(C) dimer after the 2 T4 residues are 
removed. A) RMSD plot of the entire protein and its two loops on each monomer subunit; B) RMSD plot 
of the interfacial residues on both monomer subunits; C) structures of the Dio3 dimer at 0 μs and 2 μs 
simulation time. The black line indicates the point at which the 2 T4 residues are removed. 
 
 
 To better understand the key interactions that influence these conformational changes at the 
interfacial region within the Dio3 dimer, hydrogen bonding analysis was carried out. The hydrogen 
bonding interactions were calculated using the pairwise energy decomposition analysis in MMPBSA for 
all possible residue pairings between interfacial residues (residues 267-301). The pairwise residue 
interaction energies include all hydrogen bonding instances between pairs, meaning that more than one 
potential hydrogen bonding interaction between the pairs could persist during the simulation.257 Hydrogen 
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bonds can form or be lost very rapidly over the course of an MD simulation, which could lead to large 
variances in per-residue hydrogen bonding energies and also high standard deviations (SDs) of the energy 
values.257 The magnitude of the pairwise SDs can identify whether hydrogen bonds are dynamic (if SDs 
are high) or static (if SDs are low). The data was sorted based upon the types of interactions involved (β-β 
interactions if interactions occur between interfacial β-sheet residues, etc.).  
Between the β-sheets, the strongest and most persistent hydrogen bonding interactions are β-β 
Met270-Gln272 BB-BB interactions, which anchor the β-sheets together. Even after the two T4 substrates 
are removed, the Met270-Gln272 BB-BB interactions are only destabilized by roughly 0.3 kcal mol-1 and 
the SD remains low (ΔGholo = -4.13 ± 0.38 kcal mol-1, ΔGapo = -3.84 ± 0.07 kcal mol-1) (Table 5 and 6). 
Distance plots between these backbone interactions show three of the BB-BB interactions remain static 
throughout the course of the MD simulation, with the Met270H-Gln272O interaction only being 
temporarily lost during the 0.6-0.8 µs and 1.3-1.5 µs intervals (Figure 35). Other intermittent β-β BB-BB 
interactions between the β-sheets occur during the MD simulation, including Thr268-Gln272, Met270-
Tyr271, and Ile269-Gln272. Two of the three interactions, Met270-Tyr271 and Ile269-272, become 
slightly destabilized upon removal of the 2 T4 substrates (ΔΔG = +0.19 and +0.26 kcal mol-1 respectively), 
while the interactions between Thr268-Gln272 are more destabilized by the removal of T4 substrates 
(ΔΔG = +1.32 kcal mol-1). These three interactions have low SDs and remain relatively static, similar to 
Met270-Gln272 (Table 5 and 6). Although the sequences of Dio3 and other B-type proteins differ in the 
β-sheet region, the persistence of BB-BB interactions in the β-sheets in Dio3 is a characteristic shared by 
all B-type proteins (Table 7). These interactions may be necessary to stabilize the β-sheets within the 




Figure 35. A) Distance plots of the two stable hydrogen bonds between Met270-Gln272 backbone atoms; 
B) initial and final structures of the Met270-Gln272 hydrogen bonding interactions. The black line 










Table 5. Energy of hydrogen bonds along the dimer interface region of Dio3 during the holo 
simulation. 
     Interaction    ΔG (kcal mol-1) 
β-β Interdimer 
(BB-BB) 
Met270-Gln272 -4.13 ± 0.38 
Thr268-Gln272 -1.86 ± 0.65 
 Met270-Tyr271 -2.35 ± 0.29 
 Ile269-Gln272 -2.17 ± 0.19 
α-α Interdimer 
(SC-SC) 
Arg291-Glu294 -1.17 ± 0.44 
Glu294-Gln295 -1.24 ± 0.17 




Arg291-Glu290 -0.23 ± 0.14 
Arg291-Glu294 -2.66 ± 0.59 
 
 
Table 6. Energy of hydrogen bonds along the dimer interface region of Dio3 during the apo 
simulation. 
 Interaction    ΔG (kcal mol-1) 
β-β Interdimer 
(BB-BB) 
Met270-Gln272 -3.84 ± 0.07 
Thr268-Gln272 -0.54 ± 0.50 
 Met270-Tyr271 -2.16 ± 0.30 
 Ile269-Gln272 -1.90 ± 0.31 
α-α Interdimer 
(SC-SC) 
Arg291-Glu294 -3.96 ± 1.29 
Glu294-Gln295 N/A 




Arg291-Glu290 -2.08 ± 0.83 









Table 7. List of all notable hydrogen bonds and interactions in the other B-type proteins examined 
in this study. 
    Protein Interdimer H-bonds                      Intramonomer H-bonds 
2P5R Tyr151-Arg149 (SC-SC) (turn-β) 
Thr153-Asp148 (SC-SC) (turn-β) 
Arg161-Ser158 (SC-SC) (α-α) 
Ser158-Asp162 (SC-SC) (α-α) 
Arg161-Asp162 (SC-SC)** (α-α) 
Thr154-Tyr151 (BB-BB) (α-turn) 
 
2C0D Arg154-Asp160 (SC-SC) (β-turn) 
Arg154-Asp160 (BB-BB) (β-turn) 
Val158-Gln156 (BB-BB)* (β-β) 
 
Arg154-Asp181 (SC-SC)** (β-α) 
Asn159-Ile163 (SC-BB) (turn-turn) 
Asn159-Gly164 (SC-BB) (turn-turn) 
 
4KCE Asp140-Arg134 (SC-SC) (β-β) 
Asp140-Arg134 (BB-BB) (β-β) 
Hip135-Asn139 (SC-SC) (β-β) 
Ile138-Ser136 (BB-BB)* (β-β) 
Arg152-Gly144 (SC-BB) (α-turn) 
Glu139-Asn146 (SC-SC) (α-α) 
 
Arg152-Glu149 (SC-SC)** (α-α) 
Asn139-Val143 (SC-BB) (β-turn) 
Asn139-Gly144 (SC-BB) (β-turn) 
Val143-Asp140 (BB-BB) (turn-β) 
 
4L0U Val141-Leu139 (BB-BB)* (β-β) 
Arg155-Glu152 (SC-SC) (α-α) 
Gln137-Glu152 (SC-SC) (turn-turn) 
 
N/A 
1QQ2 Ile142-Ile140 (BB-BB)* (β-β) 
Asn143-Gln139 (SC-SC) (β-β) 
Thr141-Gln139 (SC-SC) (β-β) 
Ser150-Glu153 (SC-SC) (α-α) 
Arg138-Asp165 (SC-SC)  (β-α) 
Arg156-Glu153 (SC-SC)** (α-α) 
Val147-Leu145 (BB-BB) (turn-β) 
Gly148-Leu145 (BB-BB) (turn-β) 
    *Key intermonomer BB-BB interaction. 
    **Key intramonomer SC-SC interaction. 
 
 
The interactions between the α-helices are slightly less favorable overall compared to the β-sheets 
(Table 5 and 6). Four residues near the center of the interfacial α-helix share interactions with one another 
(Arg291, Glu290, Glu294, and Gln295). Arg291 has interdimer SC-SC interactions with Glu294 and 
Gln295 and accounts the largest portion of the dimerization binding energy between the α-helices (Table 
5 and 6). Three of the interactions within the α-helices, including the intramonomer SC-SC Arg291-
Glu290, interdimer SC-SC Arg291-Glu290, and interdimer SC-SC Arg291-Gln295 interactions, become 
more favorable after the two T4 substrates are removed (ΔΔG = -2.79, -1.85, and -0.12 kcal mol-1 
respectively). In addition, the interdimer Arg291-Glu294 and Arg291-Gln295 SC-SC interactions become 
more dynamic after the T4 substrates are removed (Table 5 and 6). The intramonomer Arg291-294 
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interactions become destabilized by 1.55 kcal mol-1, while the interdimer Glu290-Gln295 interactions 
become completely lost after the two T4 residues are removed.  
Intramonomer interactions involving an Arg residue is a characteristic that Dio3 shares with some 
of the other B-type dimers examined in this study, 1QQ2, 2P5R, and 4KCE (Table 6). Dio3 was 
overlayed onto each of these structures at Arg291 to compare the orientations of the Arg residue (Figure 
36). Of these three structures, the orientations of Arg156 in 1QQ2 and Arg152 in 4KCE slightly overlay 
with that of Dio3, as they both form SC-SC interactions with Glu153 and Glu149 respectively, which is 3 
residues down the helix (Figure 36A and 36C, Table 6). However, Arg156 of Dio3 assumes a more ‘bent’ 
conformation to best accommodate the SC-SC interactions with the acidic groups of the nearby Glu 
residues (Figure 36). Arg161 of 2P5R does not overlay well, as it assumes an extended conformation with 
the inward-facing Asp162 (Figure 36B, Table 4). However, in these B-type proteins, the propensity for 
Arg residues within interfacial α-helices to form both interdimer and intramonomer interactions with 
nearby acidic sidechains (Glu/Asp) in other B-type proteins suggests these interactions are key to holding 
together the α-helices in the Dio3 dimer. In addition, Arg residues within the other B-type dimers may 
also share interactions with other nearby acidic residues that are not shown in crystal structures. For 







Figure 36. Comparison of the orientation of Arg291 in Dio3 to A) Arg156 of 1QQ2; B) Arg161 of 2P5R; 




 Conflicting viewpoints regarding dimerization of Dio3 have been ongoing in the literature. The 
structure of the dimer of the Dio3 catalytic domain was investigated using sequential and structural 
comparisons to other thioredoxin-fold proteins, protein-protein docking databases, and MD simulations. 
The conflicting hypotheses in the literature regarding the Dio3 dimer structure could be due to the 
observance of A-type and B-type dimers formed in Prx proteins. Sequential and structural comparisons of 
Dio with A-type and B-type proteins show B-type dimerization is preferable. Protein-protein docking 
databases SymmDock and GalaxyRefineComplex using the 2.0 μs structure of the Dio3(C)-T4 complex in 
a previous study produced a symmetric B-type dimer that contains a thioredoxin-fold. MD simulations of 
the constructed dimer show the protein remains stable in both the apo and holo forms, and removal of the 
T4 substrates further stabilized the protein. These models could be employed for future studies regarding 
the role of dimerization in the deiodination mechanism. MMPBSA/MMGBSA analysis identified key 
interactions within the α3β4 region of the dimerization interface. BB interactions between Met270-Gln272 
are primarily responsible for holding the β-sheets together, while intramonomer and interdimer SC-SC 
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interactions of Arg291 with Glu residues of Arg291 hold the α-helices together. The interaction energies 
within the interfacial α-helices and β-sheets are similar in magnitude and are comparable to those of other 
B-type dimers. Mutation studies involving these residues could be performed to analyze their effects on 
dimer stability and catalytic function. Although MD simulations of the Dio3 dimer show a stable 
structure, they do not contain the tether region, which may contribute to overall stability and enzymatic 
deiodination. From the computational perspective, combining the findings of this study with experimental 
studies can further discern the full-length structure of Dio3, which will be imperative for treating thyroid-
related illnesses. 
4.4 Computational Methods 
 In the Dio3 monomer structure, the CHIMERA suite was used to straighten out the interfacial β-
sheet by using the set attr function to set the dihedral angles to emulate those commonly found in β-sheets 
(φ=-120°, ψ=115°).49,258 The resulting monomer was then saved as a pdb file to be submitted to the 
SymmDock server.230 The server requires three input files; the monomer pdb file of the asymmetric unit, 
a “sites” file and a “constraints” file. The “sites” file specifies the range of residues in which the dimers 
will interact, while the “constraints” file specifies the distance constraints between pairs of atoms between 
both monomers within a certain range.230 To best allow Dio3 to dimerize according to the B-type 
description, residues within the β-sheet at the interface region were included in the “sites” file (Thr268 to 
Gln272), and the distance between the midpoints of the β-sheets, Met270, were constrained to be between 
0-7 Å. Finally, the symmetry order was set to 2 in only to consider dimer structures. Based upon the 
submitted structure, SymmDock produced 58 B-type dimers. GalaxyRefineComplex was used to resolve 
the close contacts at the interface of the best SymmDock-produced dimer by repacking the sidechain 
residues in a symmetric fashion.251 GalaxyRefineComplex produced 10 structures as an output, creating 
three structures are high quality, two that were moderate, and five that were acceptable.  
The AMBER 16 suite was used to run MD simulations using PMEDA GPU routines.259 The 
ff99sb force field was used to represent the proteins used in this study. Parameters for the deprotonated 
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Sec force field, such as bond distances, charges, and force constants, were derived according to a previous 
study.36 To ensure dimer stability, a slower approach was used during the NVT ensemble in which the 
constraints on the dimer interface are slowly released over time to allow the sidechains within the 
interface region to properly adjust. This slow approach advanced in the following steps; A) restraining the 
entire protein at a force constant of 50 kcal mol-1 Å-2; B) reducing the constraints of the protein down from 
a force constant of 50 to 25 kcal mol-1 Å-2; C) removing the constraints of the sidechains of the interfacial 
α-helices and β-sheets; D) removing the constraints of the interfacial α-helices and β-sheets entirely; E) 
removing the constraints of the sidechains remaining residues at the interface (i.e., the αβ-turn and C-
terminal residues); F) removing the constraints of the remaining residues entirely; G) reducing the 
constraints of the protein down from a force constant of 25 to 10 kcal mol-1 Å-2; H) reducing the 
constraints of the protein down from a force constant of 10 to 5 kcal mol-1 Å-2; I) full release of the entire 
protein. Modules within the AmberTools suite were used to evaluate the energetics, the hydrophobic 
contacts, and key hydrogen bonding interactions within the protein.70 MMPBSA/MMGBSA calculations 

















CHAPTER 5  
CONCLUSION 
 
 In this dissertation, in silico methods were used to model and evaluate XB interactions of known 
EDCs (PBDEs, PCBs) with a small model of the Dio3 active site and a homodimer of Dio3 was 
constructed based upon the recently isolated monomeric crystal structure. Small DFT models of 
halogenated EDCs with the SeMe- active site model show possible mechanisms of inhibition towards Dio. 
PBDEs and PCBs could inhibit Dio by forming an X—Se XB interaction to the Sec residue in the active 
site. XB favorability follows in the order of THs > PBDEs > PCBs, in agreement with larger halogens 
generally having stronger XB interactions (i.e. I > Br > Cl). THs readily undergo deiodination by 
deiodinases, with 3-T1 being the only exception. 3-T1 also displayed the weakest I—Se of the series in our 
DFT models. The inability for 3-T1 to undergo deiodination suggests a possible energy threshold needs to 
be met for dehalogenation to occur. Some of the highly substituted PBDEs/OH-BDEs have similar 
interaction energies to THs and could debrominate. On the other hand, PCBs have much less favorable 
XB interactions, suggesting dechlorination of these compounds is unlikely. The position of the XB 
interaction (i.e. ortho, meta, para) plays a role in XB strength. For diphenyl ethers (PBDEs, THs), XB is 
preferred at the ortho and meta positions. The preferential dehalogenation positions of PBDEs (ortho and 
meta) and PCBs (meta and para) suggests these halogenated aromatics could target specific Dios that 
have preferred substrates with similar substitution patterns. Sequential and structural comparisons of Dio3 
to known A-type and B-type proteins in tandem with protein-protein docking databases show B-type 
dimerization is most likely to occur in Dio3. A symmetric B-type dimer structure of Dio3 was constructed 
by SymmDock and its interfacial residues were refined by GalaxyRefineComplex. MD simulations of the 
constructed dimer show the protein remains stable in both the apo and holo forms. BB interactions within 
the β-sheets and intramonomer and interdimer SC-SC interactions within the α-helices hold the Dio3 
dimeric structure together.  
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Moving forward, the computational findings in this dissertation regarding the small model XB 
interactions of PBDEs/PCBs and the structural and sequential data of Dio3 will aid endocrinal research. 
For example, MD simulations of the Dio3-PBDE/PCB complexes could show how these EDCs bind 
within the active site of Dio and how other external factors, such as ancillary XB interactions to amino 
acids within the active site or the Ω-loop, could influence substrate binding. Full-scale models and MD 
simulations of dimeric Dio3 that include the tether region and the membrane region can also be done to 
help discern if there are key residues within the tether region that help keep the dimeric structure together. 
Bioinformatic studies of Dio3 can include sequence comparisons to other known thioredoxin-fold 
proteins not covered in this dissertation to see if any amino acids and/or regions are conserved. Utilizing 
bioinformatics tools will be helpful for deriving the functions of residues and/or regions within Dio3. 
Finally, this research could spark interest in biochemists to help expand our understanding of Dio3 by 
performing in vivo experiments to verify the results found in this dissertation. Combining in silico and in 
vivo experiments of Dio3 will be vital in designing treatments for TH-related disorders caused by Dio 
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COMPLETE TABLE OF PBDE DATA 
Compound d(Br--Se), Å d(C-Br) with 











2.919 2.018 1.904 0.114 -13.38 26.60 
XB-p’-3a-HO-
BDE-7 
2.972 1.999 1.911 0.088 -13.46 21.74 
XB-o-3-HO-
BDE-47 
2.834 2.073 1.906 0.167 -22.23 38.66 
XB-p-3-HO-
BDE-47 
2.902 2.039 1.915 0.124 -21.65 29.38 
XB-o’-3-HO-
BDE-47 
2.876 2.036 1.902 0.134 -16.84 30.88 
XB-p’-3-HO-
BDE-47 
2.948 2.006 1.910 0.096 -16.05 23.34 
XB-o-4-HO-
BDE-42 
2.818 2.069 1.896 0.173 -16.75 40.71 
XB-m-4-HO-
BDE-42 
2.852 2.060 1.907 0.153 -22.53 37.23 
XB-o’-4-HO-
BDE-42 
2.883 2.034 1.903 0.131 -16.05 30.16 
XB-p’-4-HO-
BDE-42 
2.951 2.004 1.911 0.093 -15.16 23.15 
XB-p-2a-HO-
BDE-28 
3.017 1.988 1.912 0.076 -11.62 19.15 
XB-o’-2a-HO-
BDE-28 
2.969 2.000 1.907 0.093 -15.49 22.70 
XB-p’-2a-HO-
BDE-28 
2.986 1.995 1.911 0.084 -12.93 20.96 
XB-p’-4a-HO-
BDE-49 
2.950 2.005 1.911 0.094 -14.63 23.20 
XB-o’-4a-HO-
BDE-49 
2.901 2.029 1.903 0.126 -15.69 28.76 
XB-o-4a-HO-
BDE-49 
2.881 2.032 1.901 0.131 -17.75 29.94 
XB-m-4a-HO-
BDE-49 
2.923 2.015 1.901 0.114 -14.99 26.79 
XB-p’-6a-HO-
BDE-99 
2.880 2.034 1.902 0.132 -15.88 31.64 
XB-o’-6a-HO-
BDE-99 
2.902 2.022 1.900 0.122 -15.05 28.80 
XB-m’-6a-HO-
BDE-99 
2.889 2.028 1.903 0.125 -16.55 30.56 
XB-o-6a-HO-
BDE-99 
2.852 2.046 1.901 0.145 -17.80 32.87 
XB-p-6a-HO-
BDE-99 
2.923 2.014 1.909 0.105 -17.97 24.97 
XB-p-6-HO-
BDE-82 





2.811 2.072 1.897 0.175 -16.96 42.89 
XB-o’-6-HO-
BDE-82 
2.616 2.276 1.899 0.377 -21.84 N/A 
XB-o-6-HO-
BDE-82 
2.803 2.077 1.896 0.181 -17.16 42.20 
XB-m’-6-HO-
BDE-82 
2.910 2.023 1.907 0.116 -15.59 28.02 
XB-p’-4-HO-
BDE-90 
2.939 2.008 1.909 0.099 -16.78 23.93 
XB-m-4-HO-
BDE-90 
2.859 2.055 1.913 0.142 -24.67 33.96 
XB-m*-4-HO-
BDE-90 
2.786 2.088 1.896 0.192 -20.53 45.74 
XB-o-4-HO-
BDE-90 
2.779 2.092 1.895 0.197 -20.39 47.31 
XB-o’-4-HO-
BDE-90 
2.862 2.043 1.901 0.142 -17.98 31.76 
XB-p-6-HO-
BDE-140 
2.854 2.047 1.904 0.143 -19.16 33.48 
XB-o-6-HO-
BDE-140 
2.782 2.090 1.895 0.195 -18.66 45.74 
XB-m-6-HO-
BDE-140 
2.798 2.079 1.896 0.183 -18.41 45.05 
XB-o’-6-HO-
BDE-140 
2.684 2.193 1.901 0.292 -24.47 68.73 
XB-p’-6-HO-
BDE-140 
2.911 2.020 1.908 0.112 -17.81 26.10 
XB-p-6-HO-
BDE-85 
2.855 2.049 1.904 0.145 -18.47 33.69 
XB-m-6-HO-
BDE-85 
2.806 2.075 1.897 0.178 -17.69 43.66 
XB-o-6-HO-
BDE-85 
2.798 2.080 1.896 0.184 -17.93 43.00 
XB-o’-6-HO-
BDE-85 
2.762 2.121 1.906 0.215 -21.22 48.19 
XB-p’-6-HO-
BDE-85 
2.969 2.000 1.911 0.089 -14.34 21.88 
XB-o’-5a-HO-
BDE-99 
2.848 2.047 1.900 0.147 -22.26 34.03 
XB-p’-5a-HO-
BDE-99 
2.842 2.047 1.902 0.145 -20.64 35.82 
XB-o-5a-HO-
BDE-99 
2.861 2.047 1.901 0.146 -17.26 33.13 
XB-p-5a-HO-
BDE-99 
2.908 2.023 1.901 0.122 -15.65 28.05 
XB-p’-6-HO-
BDE-157 
2.821 2.063 1.896 0.167 -17.34 41.82 
XB-m’-6-HO-
BDE-157 
2.858 2.047 1.904 0.143 -18.29 33.63 
XB-m’-6-HO-
BDE-157 
2.862 2.042 1.905 0.137 -17.48 32.44 
XB-o-6-HO-
BDE-157 





2.774 2.093 1.896 0.197 -21.04 49.71 
XB-p-6-HO-
BDE-157 
2.832 2.057 1.903 0.154 -21.77 36.07 
XB-p-6-HO-
BDE-87 
2.856 2.049 1.904 0.145 -18.42 33.64 
XB-m-6-HO-
BDE-87 
2.806 2.074 1.896 0.178 -17.61 43.73 
XB-o-6-HO-
BDE-87 
2.795 2.082 1.896 0.186 -17.81 43.36 
XB-o’-6-HO-
BDE-87 
2.753 2.111 1.905 0.206 -20.50 45.62 
XB-m’-6-HO-
BDE-87 
2.982 1.992 1.910 0.082 -13.92 21.08 
XB-p’-4a-HO-
BDE-17 
2.960 2.002 1.912 0.090 -13.91 22.54 
XB-o’-4a-HO-
BDE-17 
2.897 2.027 1.904 0.123 -14.45 28.69 
XB-o-4a-HO-
BDE-17 
2.926 2.016 1.903 0.113 -13.25 25.79 
XB-p-5-HO-
BDE-47 
2.900 2.037 1.913 0.124 -21.65 29.63 
XB-o-5-HO-
BDE-47 
2.870 2.043 1.903 0.140 -16.53 31.85 
XB-o’-5-HO-
BDE-47 
2.878 2.035 1.901 0.134 -16.62 30.59 
XB-p’-5-HO-
BDE-47 
2.935 2.009 1.909 0.100 -14.15 24.21 
XB-p-6-HO-
BDE-47 
2.941 2.013 1.909 0.104 -17.57 24.65 
XB-o-6-HO-
BDE-47 
2.863 2.042 1.901 0.141 -16.97 31.62 
XB-o’-6-HO-
BDE-47 
2.778 2.109 1.903 0.206 -17.51 44.77 
XB-p’-6-HO-
BDE-47 
2.929 2.013 1.911 0.102 -12.44 21.12 
XB-p-3a-HO-
BDE-154 
2.818 2.080 1.906 0.174 -23.90 41.55 
XB-m-3a-HO-
BDE-154 
2.849 2.045 1.901 0.144 -19.79 33.91 
XB-o-3a-HO-
BDE-154 
2.804 2.098 1.896 0.202 -25.46 44.57 
XB-o’-3a-HO-
BDE-154 
2.807 2.072 1.901 0.171 -25.04 39.12 
XB-p’-3a-HO-
BDE-154 
2.885 2.028 1.908 0.120 -23.68 28.29 
XB-p’-3a-HO-
BDE-28 
2.956 2.003 1.915 0.088 -15.12 22.79 
XB-o’-3a-HO-
BDE-28 
2.903 2.024 1.903 0.121 -15.36 28.18 
XB-p-3a-HO-
BDE-28 
2.955 2.017 1.910 0.107 -18.24 24.85 
XB-m-BDE-99 2.852 2.041 1.902 0.139 -19.59 34.29 
XB-p’-BDE-99 2.935 2.009 1.909 0.100 -16.89 24.25 
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XB-o-BDE-99 2.840 2.051 1.900 0.151 -19.50 35.12 
XB-p-BDE-99 2.846 2.046 1.902 0.144 -19.90 35.07 
XB-o’-BDE-99 2.858 2.044 1.901 0.143 -18.29 32.93 
XB-o-BDE-47 2.869 2.039 1.903 0.136 -17.54 31.64 
XB-p-BDE-47 2.943 2.007 1.911 0.096 -16.62 23.03 
XB-p-BDE-153 2.839 2.049 1.900 0.149 -20.64 35.91 
XB-o-BDE-153 2.826 2.059 1.899 0.160 -20.69 37.04 
XB-m-BDE-153 2.843 2.046 1.899 0.147 -20.39 35.70 
XB-o-BDE-209 2.813 2.068 1.894 0.174 -28.22 40.87 
XB-m-BDE-209 2.816 2.060 1.895 0.165 -26.78 39.19 
















































































COMPLETE TABLE OF PCB DATA 
 
Compound d(Cl—Se), Å Δd(C-Cl), Å 
ΔE + ZPE, kcal 
mol-1 ΔED→A, kcal mol-1 %X 
XB-3-PCB-2 3.468 -0.010 -2.02 2.79 45.14 
XB-4-PCB-3 3.441 -0.010 -2.28 3.16 45.19 
XB-3-PCB-5 3.509 -0.008 -3.31 2.13 46.24 
XB-2-PCB-6 3.391 -0.007 -1.81 4.07 45.13 
XB-3'-PCB-6 3.428 -0.008 -2.45 3.49 45.20 
XB-4-PCB-7 3.366 -0.007 -4.06 4.05 45.59 
XB-4'-PCB-8 3.470 -0.012 -2.45 2.71 45.24 
XB-5-PCB-9 3.381 -0.007 -3.96 3.91 45.51 
XB-2-PCB-10 3.438 -0.005 -4.01 3.49 45.58 
XB-3-PCB-11 3.515 -0.012 -3.22 2.06 45.30 
XB-4-PCB-12 3.514 -0.010 -3.91 2.02 46.37 
XB-3-PCB-13 3.414 -0.009 -3.44 3.53 45.24 
XB-4'-PCB-13 3.406 -0.009 -6.24 3.77 45.32 
XB-3-PCB-14 3.350 -0.006 -5.84 4.53 45.54 
XB-4-PCB-15 3.411 -0.010 -3.73 3.47 45.30 
XB-2-PCB-16 3.347 -0.001 -2.16 4.94 46.46 
XB-3-PCB-16 3.551 -0.009 -3.43 1.79 46.33 
XB-4-PCB-17 3.337 -0.006 -4.48 3.97 45.32 
XB-2'-PCB-18 3.450 -0.010 -5.12 3.20 45.28 
XB-2-PCB-18 3.493 -0.014 -4.09 2.34 45.52 
XB-5-PCB-18 3.374 -0.008 -4.75 4.00 45.60 
XB-2-PCB-19 3.379 -0.004 -4.62 3.90 45.62 
XB-2'-PCB-19 3.482 -0.008 -4.47 2.93 45.30 
XB-2-PCB-20 3.304 0.001 -3.55 4.71 46.37 
XB-3'-PCB-20 3.505 -0.012 -2.74 2.16 45.34 
101 
 
XB-3-PCB-20 3.487 -0.008 -4.50 2.26 46.36 
XB-3-PCB-21 3.255 0.007 -3.68 5.68 47.31 
XB-4-PCB-21 3.443 -0.007 -5.37 2.67 46.56 
XB-3-PCB-22 3.478 -0.007 -4.73 2.39 46.34 
XB-4'-PCB-22 3.410 -0.009 -3.46 3.75 45.32 
XB-2-PCB-23 3.339 0.002 -6.34 4.50 46.56 
XB-3-PCB-23 3.301 0.000 -5.68 4.32 46.59 
XB-5-PCB-23 3.320 -0.004 -5.68 4.04 45.84 
XB-3-PCB-24 3.482 -0.007 -5.59 2.27 46.56 
XB-3'-PCB-25 3.518 -0.013 -3.08 2.03 45.34 
XB-4-PCB-25 3.371 -0.009 -5.47 3.76 45.69 
XB-2-PCB-26 3.437 -0.008 -4.86 2.85 45.56 
XB-3'-PCB-26 3.418 -0.010 -3.24 3.39 45.35 
XB-5-PCB-26 3.370 -0.008 -5.52 3.90 45.62 
XB-3'-PCB-27 3.451 -0.010 -2.01 2.97 45.29 
XB-4'-PCB-28 3.402 -0.009 -3.54 3.85 45.33 
XB-4-PCB-28 3.357 -0.008 -5.27 4.00 45.69 
XB-4-PCB-29 3.298 -0.001 -5.64 4.32 46.70 
XB-5-PCB-29 3.553 -0.009 -5.95 1.57 46.62 
XB-2-PCB-30 3.349 -0.001 -6.34 3.91 45.85 
XB-4-PCB-30 3.284 -0.001 -6.01 4.76 45.94 
XB-2-PCB-31 3.411 -0.005 -7.33 3.34 45.47 
XB-4'-PCB-31 3.412 -0.009 -3.48 3.45 45.35 
XB-5-PCB-31 3.360 -0.007 -5.60 4.18 45.61 
XB-2-PCB-32 3.441 -0.008 -5.24 2.81 45.52 
XB-4'-PCB-32 3.421 -0.009 -2.37 3.46 45.27 
XB-2-PCB-33 3.446 -0.009 -4.11 2.76 45.23 
XB-3'-PCB-33 3.355 -0.003 -2.65 4.60 46.41 
XB-4'-PCB-33 3.517 -0.010 -4.05 1.98 46.39 
XB-5'-PCB-34 3.355 -0.005 -4.57 4.48 45.64 
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XB-3'-PCB-35 3.378 -0.007 -4.26 4.04 45.37 
XB-3-PCB-35 3.326 0.000 -3.89 4.33 46.44 
XB-4-PCB-35 3.501 -0.009 -5.03 2.09 46.46 
XB-3'-PCB-36 3.411 -0.010 -4.46 3.35 45.40 
XB-3-PCB-36 3.314 -0.004 -5.28 4.26 45.65 
XB-4-PCB-37 3.465 -0.009 -5.35 2.45 46.46 
XB-3-PCB-38 3.538 -0.008 -6.20 1.67 46.52 
XB-4-PCB-38 3.248 0.007 -4.51 6.22 47.41 
XB-3-PCB-39 3.315 -0.005 -5.83 4.27 45.64 
XB-4'-PCB-39 3.356 -0.009 -5.03 4.41 45.43 
XB-3-PCB-40 3.452 -0.008 -4.67 2.65 46.41 
XB-3-PCB-41 3.257 0.007 -3.53 5.68 47.38 
XB-4-PCB-41 3.451 -0.007 -5.26 2.56 46.58 
XB-2-PCB-42 3.302 0.000 -3.62 4.64 46.50 
XB-3-PCB-42 3.472 -0.008 -4.62 2.44 46.41 
XB-4'-PCB-42 3.374 -0.008 -5.27 3.73 45.69 
XB-2'-PCB-43 3.396 -0.006 -3.73 3.65 45.44 
XB-3-PCB-43 3.309 -0.001 -5.27 4.06 46.67 
XB-5-PCB-43 3.312 -0.005 -5.83 4.16 45.89 
XB-2'-PCB-45 3.456 -0.007 -5.63 2.52 45.37 
XB-3-PCB-45 3.434 -0.006 -5.53 2.81 46.63 
XB-6-PCB-45 3.358 -0.005 -6.29 3.91 45.86 
XB-2-PCB-46 3.329 0.000 -3.31 4.40 46.44 
XB-3-PCB-46 3.499 -0.009 -3.66 2.18 46.38 
XB-2-PCB-47 3.318 -0.004 -4.99 3.96 45.75 
XB-4-PCB-47 3.319 -0.006 -5.81 4.18 45.71 
XB-2'-PCB-48 3.357 -0.006 -3.96 3.53 45.41 
XB-4-PCB-48 3.287 0.000 -5.52 4.52 46.72 
XB-5-PCB-48 3.307 -0.001 -5.82 4.18 46.67 
XB-2-PCB-49 3.318 -0.003 -5.01 3.97 45.77 
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XB-4-PCB-49 3.366 -0.007 -5.35 3.86 45.72 
XB-2'-PCB-49 3.371 -0.005 -5.15 3.89 45.73 
XB-5'-PCB-49 3.388 -0.007 -5.53 3.58 45.67 
XB-2'-PCB-50 3.390 -0.007 -3.59 3.99 45.35 
XB-4-PCB-50 3.304 -0.003 -6.43 4.37 45.97 
XB-2-PCB-51 3.339 -0.004 -4.49 3.90 45.69 
XB-4-PCB-51 3.355 -0.007 -4.45 4.18 45.65 
XB-2-PCB-52 3.359 0.004 -5.36 3.33 45.74 
XB-5-PCB-52 3.354 -0.007 -5.49 4.26 45.68 
XB-2'-PCB-53 3.388 -0.005 -5.06 3.56 45.70 
XB-2-PCB-53 3.354 -0.004 -4.45 3.61 45.66 
XB-5-PCB-53 3.385 -0.007 -4.18 3.73 45.63 
XB-2-PCB-54 3.358 -0.006 -4.09 3.62 45.63 
XB-2-PCB-55 3.243 0.005 -5.56 5.16 45.28 
XB-3'-PCB-55 3.490 -0.012 -3.74 2.26 44.97 
XB-3-PCB-55 3.238 0.008 -5.43 6.01 46.89 
XB-4-PCB-55 3.454 -0.007 -6.93 2.49 46.39 
XB-2-PCB-56 3.253 0.001 -4.45 5.28 46.39 
XB-3'-PCB-56 3.331 0.000 -3.71 4.26 46.50 
XB-3-PCB-56 3.464 -0.009 -5.63 2.45 46.42 
XB-4'-PCB-56 3.505 -0.009 -5.15 2.07 46.45 
XB-2-PCB-57 3.245 0.005 -5.67 5.14 46.67 
XB-3'-PCB-57 3.419 -0.010 -4.01 3.25 45.44 
XB-3-PCB-57 3.339 -0.004 -6.70 3.49 46.69 
XB-5-PCB-57 3.295 -0.003 -6.95 4.64 45.94 
XB-2-PCB-58 3.374 -0.009 -8.93 4.85 46.43 
XB-3'-PCB-58 3.337 -0.007 -4.89 3.78 45.69 
XB-3-PCB-58 3.382 -0.005 -6.00 3.47 46.46 
XB-3'-PCB-59 3.432 -0.009 -3.23 3.13 45.37 
XB-3-PCB-59 3.406 -0.006 -6.88 3.09 46.66 
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XB-3-PCB-60 3.229 0.005 -5.61 6.23 47.31 
XB-4'-PCB-60 3.390 -0.006 -4.28 3.96 45.51 
XB-4-PCB-60 3.416 -0.004 -6.88 2.92 46.77 
XB-3-PCB-61 3.224 0.012 -5.83 6.27 47.49 
XB-4-PCB-61 3.218 0.012 -6.14 6.44 47.57 
XB-5-PCB-61 3.252 0.003 -7.18 5.26 46.78 
XB-3-PCB-62 3.220 0.011 -6.16 6.41 47.56 
XB-4-PCB-62 3.256 0.003 -6.94 4.93 46.86 
XB-6-PCB-62 3.268 0.002 -7.18 4.80 46.11 
XB-3-PCB-63 3.258 0.002 -7.03 5.25 46.68 
XB-5-PCB-63 3.279 -0.003 -7.07 4.81 45.93 
XB-3-PCB-64 3.443 -0.008 -7.18 2.63 46.64 
XB-6-PCB-64 3.327 -0.005 -6.83 3.84 45.83 
XB-4'-PCB-64 3.411 -0.009 -3.00 3.72 45.35 
XB-2-PCB-65 3.237 0.007 -6.70 4.91 46.88 
XB-3-PCB-65 3.249 0.005 -7.08 5.17 46.85 
XB-2-PCB-66 3.281 -0.002 -5.97 4.49 45.63 
XB-3'-PCB-66 3.329 -0.001 -4.03 4.28 46.50 
XB-4'-PCB-66 3.484 -0.009 -5.36 2.24 46.47 
XB-4-PCB-66 3.341 -0.007 -6.56 3.56 45.76 
XB-2-PCB-67 3.266 0.000 -6.61 4.78 45.88 
XB-4-PCB-67 3.321 -0.002 -6.74 3.79 46.78 
XB-5-PCB-67 3.281 0.002 -6.44 5.05 46.71 
XB-3'-PCB-67 3.445 -0.010 -4.25 2.86 45.42 
XB-2-PCB-68 3.268 -0.001 -6.61 4.75 45.67 
XB-3'-PCB-68 3.301 -0.004 -5.40 4.61 45.71 
XB-4-PCB-68 3.321 -0.006 -6.92 3.94 45.79 
XB-5'-PCB-68 3.321 -0.004 -5.76 4.17 45.75 
XB-2-PCB-69 3.278 0.001 -7.89 4.48 45.97 
XB-3'-PCB-69 3.431 -0.009 -3.38 3.14 45.40 
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XB-4-PCB-69 3.291 -0.002 -7.09 4.59 46.03 
XB-2-PCB-70 3.385 -0.006 -6.26 3.41 45.60 
XB-3'-PCB-70 3.325 0.000 -4.05 4.44 46.50 
XB-4'-PCB-70 3.467 -0.009 -5.01 2.41 46.49 
XB-5-PCB-70 3.341 -0.005 -6.51 3.74 45.70 
XB-2-PCB-71 3.423 -0.007 -6.68 2.90 45.63 
XB-3'-PCB-71 3.446 -0.007 -3.66 2.64 46.46 
XB-4'-PCB-71 3.479 -0.009 -3.92 2.36 46.41 
XB-2-PCB-72 3.298 -0.003 -6.73 4.22 45.63 
XB-5-PCB-72 3.361 -0.007 -6.40 3.93 45.75 
XB-3'-PCB-72 3.313 -0.004 -5.62 4.20 45.75 
XB-2-PCB-73 3.422 -0.006 -6.49 3.02 45.66 
XB-3'-PCB-73 3.321 -0.005 -4.49 4.45 45.70 
XB-4'-PCB-74 3.392 -0.010 -4.40 3.68 45.52 
XB-4-PCB-74 3.275 0.001 -6.82 4.64 46.78 
XB-5-PCB-74 3.323 -0.003 -6.92 3.67 46.70 
XB-4'-PCB-75 3.407 -0.008 -3.28 3.80 45.36 
XB-4-PCB-75 3.253 -0.001 -7.75 5.27 46.04 
XB-2-PCB-76 3.351 -0.005 -5.31 3.43 45.29 
XB-3'-PCB-76 3.260 0.003 -6.30 5.25 46.61 
XB-4'-PCB-76 3.258 0.008 -4.05 5.72 47.44 
XB-3-PCB-77 3.285 0.001 -5.08 4.49 46.51 
XB-4-PCB-77 3.279 -0.001 -5.62 5.28 46.53 
XB-3'-PCB-78 3.416 -0.010 -5.16 3.15 45.46 
XB-3-PCB-78 3.293 0.000 -6.63 4.15 46.61 
XB-4-PCB-78 3.223 0.009 -5.65 6.60 47.50 
XB-3'-PCB-79 3.301 -0.004 -6.41 4.40 45.73 
XB-3-PCB-79 3.547 -0.010 -6.10 1.59 46.53 
XB-4-PCB-79 3.445 -0.008 -6.16 2.59 46.55 
XB-3-PCB-80 3.299 -0.004 -6.71 4.42 45.78 
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XB-3-PCB-81 3.631 -0.009 -7.45 1.13 46.61 
XB-4-PCB-81 3.240 0.010 -5.39 6.01 47.49 
XB-4'-PCB-81 3.361 -0.008 -5.62 4.09 45.48 
XB-2'-PCB-82 3.361 -0.001 -7.35 3.71 46.52 
XB-3'-PCB-82 3.418 -0.007 -5.46 3.01 46.47 
XB-3-PCB-82 3.232 0.009 -5.06 6.11 47.46 
XB-4-PCB-82 3.433 -0.006 -6.74 2.69 46.64 
XB-2'-PCB-83 3.351 -0.001 -7.21 3.79 46.57 
XB-3'-PCB-83 3.453 -0.008 -5.53 2.55 46.49 
XB-3-PCB-83 3.316 -0.003 -6.33 3.85 46.74 
XB-5-PCB-83 3.292 -0.002 -6.78 4.41 45.98 
XB-2'-PCB-84 3.391 0.000 -6.82 3.42 46.50 
XB-3'-PCB-84 3.498 -0.008 -4.34 2.15 46.45 
XB-2-PCB-84 3.392 0.000 -6.82 3.41 46.73 
XB-3-PCB-84 3.319 -0.002 -6.46 3.86 46.69 
XB-2-PCB-85 3.236 0.006 -6.02 5.37 46.69 
XB-3-PCB-85 3.228 0.008 -5.43 6.19 47.46 
XB-2'-PCB-85 3.378 0.001 -8.57 3.62 45.79 
XB-4'-PCB-85 3.327 -0.006 -6.11 3.99 45.75 
XB-4-PCB-85 3.388 -0.005 -6.89 3.24 46.66 
XB-2'-PCB-86 3.422 -0.007 -7.04 2.77 45.47 
XB-3-PCB-86 3.205 0.014 -5.82 6.81 47.57 
XB-4-PCB-86 3.213 0.011 -6.33 6.52 47.59 
XB-5-PCB-86 3.269 0.001 -7.49 4.57 46.82 
XB-3-PCB-87 3.230 0.010 -5.67 6.16 47.47 
XB-4-PCB-87 3.423 -0.006 -6.72 2.82 46.66 
XB-5'-PCB-87 3.348 -0.006 -6.56 4.25 45.72 
XB-2'-PCB-88 3.364 -0.006 -4.34 3.41 45.40 
XB-3-PCB-88 3.222 0.011 -6.06 6.26 47.62 
XB-4-PCB-88 3.217 0.007 -7.55 5.90 46.89 
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XB-2-PCB-89 3.270 0.004 -5.28 4.80 46.64 
XB-3-PCB-89 3.241 0.008 -4.17 5.93 47.43 
XB-4-PCB-89 3.272 0.001 -5.67 4.93 46.61 
XB-3-PCB-90 3.279 0.000 -6.79 4.57 46.73 
XB-4'-PCB-90 3.353 -0.007 -6.37 4.01 45.79 
XB-5-PCB-90 3.276 -0.001 -7.39 4.66 45.99 
XB-2'-PCB-90 3.362 -0.004 -8.50 3.37 45.82 
XB-3-PCB-91 3.405 -0.004 -6.75 3.08 46.71 
XB-4'-PCB-91 3.328 -0.005 -5.33 3.92 45.73 
XB-6-PCB-91 3.319 0.001 -8.82 4.31 45.97 
XB-2'-PCB-92 3.374 -0.006 -8.30 3.23 45.79 
XB-2-PCB-92 3.254 0.004 -6.12 5.04 46.80 
XB-3-PCB-92 3.290 0.001 -6.71 4.31 46.76 
XB-5'-PCB-92 3.356 -0.007 -6.20 4.02 45.76 
XB-5-PCB-92 3.289 -0.003 -6.87 4.42 46.00 
XB-2'-PCB-93 3.433 -0.008 -6.96 2.70 45.39 
XB-3-PCB-93 3.242 0.005 -7.40 5.28 46.90 
XB-2'-PCB-94 3.328 -0.004 -6.26 3.56 45.73 
XB-2-PCB-94 3.278 0.004 -5.80 4.84 46.74 
XB-3-PCB-94 3.294 0.001 -5.70 4.32 46.73 
XB-5-PCB-94 3.300 -0.003 -5.84 4.29 45.97 
XB-2'-PCB-95 3.324 -0.002 -5.47 4.00 45.72 
XB-2-PCB-95 3.244 0.005 -5.82 5.14 46.75 
XB-3-PCB-95 3.343 -0.002 -6.72 3.46 46.73 
XB-5'-PCB-95 3.338 -0.005 -4.97 4.01 45.73 
XB-6-PCB-95 3.304 0.000 -7.01 3.91 45.98 
XB-2'-PCB-96 3.333 -0.003 -5.57 3.77 45.70 
XB-2-PCB-96 3.259 0.006 -5.57 5.26 46.74 
XB-3-PCB-96 3.453 -0.007 -5.69 2.55 46.68 
XB-6-PCB-96 3.284 -0.001 -6.33 4.85 45.93 
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XB-2-PCB-97 3.261 0.003 -5.08 5.23 46.55 
XB-3-PCB-97 3.399 -0.006 -5.82 3.24 46.48 
XB-4'-PCB-97 3.278 0.001 -6.61 4.64 46.74 
XB-5'-PCB-97 3.282 0.002 -6.83 4.63 46.78 
XB-3-PCB-98 3.457 -0.009 -4.81 2.56 46.45 
XB-2'-PCB-98 3.335 0.000 -8.87 4.11 46.02 
XB-4'-PCB-98 3.258 0.000 -7.35 5.19 46.05 
XB-2-PCB-99 3.278 0.001 -6.95 4.64 46.04 
XB-2'-PCB-99 3.278 -0.001 -6.17 4.58 45.81 
XB-4'-PCB-99 3.342 -0.007 -6.38 3.57 45.78 
XB-5-PCB-99 3.257 0.004 -6.48 5.22 46.76 
XB-4-PCB-99 3.268 0.001 -6.83 4.77 46.79 
XB-2'-PCB-100 3.295 -0.003 -5.82 4.43 45.73 
XB-4-PCB-100 3.266 -0.001 -7.32 4.80 46.06 
XB-4'-PCB-100 3.362 -0.007 -5.70 3.92 45.73 
XB-2'-PCB-101 3.340 -0.004 -6.28 3.43 45.78 
XB-2-PCB-101 3.278 0.000 -6.66 4.61 46.06 
XB-4-PCB-101 3.275 0.001 -6.68 4.60 46.80 
XB-5'-PCB-101 3.326 -0.006 -6.33 3.93 45.75 
XB-5-PCB-101 3.254 0.003 -6.24 5.22 46.77 
XB-2-PCB-102 3.287 0.001 -6.39 4.63 46.00 
XB-4-PCB-102 3.287 0.000 -5.55 4.44 46.73 
XB-5-PCB-102 3.298 0.002 -5.29 4.68 46.74 
XB-2'-PCB-102 3.446 -0.005 -6.42 2.66 45.69 
XB-2'-PCB-103 3.323 -0.003 -6.01 4.02 45.72 
XB-2-PCB-103 3.263 0.004 -7.54 4.71 46.07 
XB-4-PCB-103 3.261 -0.001 -7.40 4.99 46.05 
XB-5'-PCB-103 3.382 -0.006 -5.50 3.61 45.74 
XB-2'-PCB-104 3.327 -0.003 -5.50 3.91 45.68 
XB-2-PCB-104 3.270 0.001 -6.36 4.93 46.00 
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XB-4-PCB-104 3.294 -0.001 -6.04 4.61 46.01 
XB-2-PCB-105 3.316 -0.006 -10.89 2.94 46.60 
XB-3-PCB-105 3.221 0.011 -6.45 6.44 47.46 
XB-4-PCB-105 3.375 -0.005 -7.75 2.90 46.70 
XB-3'-PCB-105 3.311 0.000 -4.58 4.55 46.55 
XB-4'-PCB-105 3.487 -0.009 -5.87 2.18 46.52 
XB-2-PCB-106 3.199 0.007 -7.25 5.79 46.82 
XB-3'-PCB-106 3.396 -0.009 -4.58 3.62 45.48 
XB-3-PCB-106 3.187 0.014 -7.39 7.15 47.58 
XB-4-PCB-106 3.198 0.013 -7.52 6.88 47.64 
XB-5-PCB-106 3.431 -0.008 -8.68 2.47 46.86 
XB-3'-PCB-107 3.299 0.002 -5.01 4.79 46.59 
XB-3-PCB-107 3.236 0.004 -7.85 5.45 46.75 
XB-5-PCB-107 3.261 -0.001 -8.19 5.05 46.02 
XB-4'-PCB-107 3.474 -0.010 -5.96 2.31 46.54 
XB-3'-PCB-108 3.300 -0.004 -5.89 4.41 45.80 
XB-3-PCB-108 3.210 0.011 -6.49 6.64 47.49 
XB-4-PCB-108 3.270 0.000 -7.78 4.65 46.73 
XB-3'-PCB-109 3.379 -0.008 -4.10 3.93 45.45 
XB-3-PCB-109 3.202 0.013 -7.37 6.91 47.66 
XB-4-PCB-109 3.233 0.005 -8.47 5.36 46.95 
XB-3'-PCB-110 3.534 -0.008 -4.54 1.76 46.53 
XB-4'-PCB-110 3.455 -0.009 -4.57 2.55 46.49 
XB-2-PCB-110 3.223 0.007 -6.33 5.24 46.73 
XB-3-PCB-110 3.364 -0.004 -7.65 3.10 46.72 
XB-6-PCB-110 3.318 -0.011 -7.58 3.82 45.90 
XB-3'-PCB-111 3.316 -0.004 -6.19 4.12 45.81 
XB-3-PCB-111 3.259 0.003 -8.18 4.92 46.78 
XB-5'-PCB-111 3.299 -0.002 -6.59 4.50 45.84 
XB-5-PCB-111 3.281 -0.002 -8.18 4.53 46.06 
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XB-3-PCB-112 3.239 0.006 -8.36 5.12 46.94 
XB-3'-PCB-112 3.442 -0.010 -3.88 2.88 45.45 
XB-2-PCB-112 3.241 0.004 -9.02 4.73 46.95 
XB-2-PCB-113 3.200 0.006 -6.61 5.20 46.77 
XB-3'-PCB-113 3.329 -0.005 -5.18 3.97 45.77 
XB-3-PCB-113 3.325 -0.002 -7.86 3.69 46.75 
XB-6-PCB-113 3.292 0.000 -9.17 4.49 45.98 
XB-3-PCB-114 3.023 -0.007 -7.81 7.29 47.56 
XB-4-PCB-114 3.198 0.014 -7.67 6.94 47.64 
XB-5-PCB-114 3.270 0.002 -8.67 4.47 46.86 
XB-4'-PCB-114 3.363 -0.008 -5.03 4.25 45.47 
XB-3-PCB-115 3.194 0.013 -7.48 7.08 47.64 
XB-4'-PCB-115 3.401 -0.010 -4.24 3.52 45.41 
XB-6-PCB-115 3.237 0.003 -8.78 5.24 46.16 
XB-4-PCB-115 3.228 0.005 -8.53 5.49 46.94 
XB-3-PCB-116 3.187 0.014 -7.49 7.03 47.71 
XB-4-PCB-116 3.167 0.021 -7.84 7.80 47.72 
XB-3-PCB-117 3.266 0.001 -8.63 4.69 46.93 
XB-4'-PCB-117 3.392 -0.009 -4.37 3.65 45.42 
XB-2-PCB-118 3.344 -0.001 -10.70 4.17 45.91 
XB-4-PCB-118 3.263 0.001 -7.81 4.85 46.84 
XB-5-PCB-118 3.265 0.003 -7.34 5.24 46.78 
XB-3'-PCB-118 3.300 0.001 -4.97 4.77 46.57 
XB-4'-PCB-118 3.437 -0.008 -6.07 2.69 46.55 
XB-3'-PCB-119 3.323 -0.001 -4.29 4.39 46.53 
XB-4'-PCB-119 3.472 -0.009 -5.01 2.35 46.49 
XB-2-PCB-119 3.290 0.002 -9.98 4.87 46.00 
XB-4-PCB-119 3.258 -0.002 -8.29 4.94 46.10 
XB-3'-PCB-120 3.315 -0.004 -6.28 4.12 45.81 
XB-4-PCB-120 3.253 0.002 -7.69 4.97 46.87 
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XB-5-PCB-120 3.296 -0.002 -7.80 4.04 46.81 
XB-2-PCB-121 3.208 0.005 -8.86 6.24 46.03 
XB-3'-PCB-121 3.320 -0.003 -7.10 4.31 45.78 
XB-4-PCB-121 3.257 0.000 -8.85 4.91 46.13 
XB-3-PCB-122 3.380 -0.005 -6.66 3.46 46.50 
XB-4'-PCB-122 3.245 0.009 -5.15 5.92 47.50 
XB-3'-PCB-122 3.266 0.005 -5.92 5.30 46.64 
XB-3'-PCB-123 3.261 0.004 -6.12 5.44 46.66 
XB-4'-PCB-123 3.231 0.008 -5.92 6.05 47.50 
XB-2-PCB-123 3.363 -0.014 -11.48 1.84 45.68 
XB-4-PCB-123 3.306 -0.005 -7.57 4.14 45.84 
XB-2-PCB-124 3.286 -0.003 -8.13 4.31 45.64 
XB-3'-PCB-124 3.340 -0.004 -6.65 3.31 46.69 
XB-4'-PCB-124 3.229 0.009 -5.69 6.28 47.52 
XB-5-PCB-124 3.355 -0.008 -7.40 3.98 45.79 
XB-2-PCB-125 3.431 -0.007 -7.47 2.84 45.68 
XB-3'-PCB-125 3.455 -0.006 -5.91 2.40 46.66 
XB-4'-PCB-125 3.237 0.008 -4.74 6.32 47.46 
XB-4-PCB-126 3.211 0.009 -6.56 6.43 47.55 
XB-3'-PCB-126 3.588 -0.009 -6.99 1.34 46.57 
XB-4'-PCB-126 3.305 -0.004 -6.93 4.12 46.60 
XB-3'-PCB-127 3.285 -0.001 -7.37 4.61 45.83 
XB-3-PCB-127 3.485 -0.008 -7.93 1.98 46.72 
XB-4-PCB-127 3.212 0.010 -6.86 6.50 47.57 
XB-3-PCB-128 3.229 0.004 -8.62 5.60 46.76 
XB-4-PCB-128 3.212 0.012 -7.25 6.72 47.61 
XB-2'-PCB-129 3.244 0.004 -5.28 5.59 46.58 
XB-3'-PCB-129 3.438 -0.008 -6.26 2.67 46.53 
XB-3-PCB-129 3.186 0.014 -7.04 7.12 47.62 
XB-4-PCB-129 3.199 0.013 -7.34 6.85 47.64 
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XB-5-PCB-129 3.228 0.005 -8.34 5.75 46.89 
XB-2-PCB-130 3.218 0.008 -6.90 5.61 46.76 
XB-2'-PCB-130 3.308 0.008 -9.37 4.16 46.82 
XB-3'-PCB-130 3.226 0.003 -7.45 5.90 46.72 
XB-3-PCB-130 3.211 0.010 -6.24 6.56 47.52 
XB-4-PCB-130 3.307 -0.002 -7.72 3.91 46.72 
XB-5'-PCB-130 3.268 -0.001 -8.18 4.78 46.04 
XB-3'-PCB-131 3.428 -0.007 -5.46 2.83 46.51 
XB-3-PCB-131 3.188 0.015 -7.19 7.19 47.52 
XB-4-PCB-131 3.307 0.000 -8.43 3.91 46.72 
XB-3'-PCB-132 3.323 -0.002 -7.77 3.73 46.75 
XB-3-PCB-132 3.228 0.010 -5.31 6.20 47.49 
XB-4-PCB-132 3.311 -0.002 -6.49 3.86 46.68 
XB-2-PCB-133 3.293 0.002 -11.81 4.54 46.86 
XB-3-PCB-133 3.286 0.000 -7.71 4.28 46.81 
XB-5-PCB-133 3.261 -0.001 -7.77 4.88 46.08 
XB-2'-PCB-134 3.359 -0.002 -8.16 3.75 46.99 
XB-3'-PCB-134 3.413 -0.006 -5.48 3.03 46.96 
XB-3-PCB-134 3.245 0.003 -8.09 5.13 46.51 
XB-3-PCB-136 3.331 -0.002 -6.57 3.62 46.75 
XB-6-PCB-136 3.279 -0.001 -7.10 4.63 45.99 
XB-2'-PCB-137 3.273 -0.002 -6.49 4.57 45.84 
XB-4'-PCB-137 3.334 -0.006 -7.15 3.64 45.83 
XB-2-PCB-137 3.207 0.008 -7.87 5.89 46.93 
XB-3-PCB-137 3.183 0.014 -7.59 7.22 47.62 
XB-4-PCB-137 3.190 0.014 -7.46 7.03 47.65 
XB-5-PCB-137 3.233 0.007 -8.26 5.76 46.91 
XB-2-PCB-138 3.213 0.008 -7.20 5.67 46.74 
XB-3-PCB-138 3.211 0.012 -6.55 6.62 47.52 
XB-2'-PCB-138 3.263 -0.001 -7.76 4.77 46.06 
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XB-4-PCB-138 3.247 0.003 -7.81 5.37 46.72 
XB-4'-PCB-138 3.255 0.002 -7.52 5.01 46.84 
XB-5'-PCB-138 3.243 0.005 -7.67 5.57 46.79 
XB-3-PCB-139 3.187 0.014 -7.58 7.04 47.70 
XB-4'-PCB-139 3.314 -0.005 -6.31 4.08 45.78 
XB-4-PCB-139 3.209 0.009 -8.83 6.06 46.96 
XB-6-PCB-139 3.233 0.004 -9.65 5.46 46.23 
XB-2-PCB-140 3.229 0.007 -6.70 5.69 46.68 
XB-3-PCB-140 3.220 0.012 -5.69 6.43 47.50 
XB-4-PCB-140 3.285 0.000 -6.73 4.40 46.67 
XB-4'-PCB-140 3.256 -0.001 -8.20 4.95 46.10 
XB-2-PCB-141 3.212 0.008 -7.93 5.58 46.95 
XB-3-PCB-141 3.173 0.016 -7.42 7.54 47.63 
XB-4-PCB-141 3.185 0.015 -7.22 7.32 47.66 
XB-5'-PCB-141 3.357 -0.007 -6.93 3.93 45.80 
XB-5-PCB-141 3.215 0.006 -8.18 6.05 46.92 
XB-2'-PCB-142 3.359 -0.005 -4.75 3.40 45.44 
XB-3-PCB-142 3.174 0.018 -7.50 7.45 47.76 
XB-4-PCB-142 3.154 0.022 -7.80 8.18 47.74 
XB-2'-PCB-143 3.297 -0.003 -7.17 3.94 45.74 
XB-2-PCB-143 3.232 0.008 -7.27 5.79 46.89 
XB-3-PCB-143 3.190 0.015 -6.21 6.94 47.60 
XB-4-PCB-143 3.202 0.013 -6.51 6.74 47.60 
XB-5-PCB-143 3.240 0.005 -6.95 5.23 46.90 
XB-2'-PCB-144 3.302 -0.003 -6.55 4.28 45.74 
XB-2-PCB-144 3.182 0.014 -8.23 6.38 46.96 
XB-3-PCB-144 3.192 0.014 -7.39 6.88 47.71 
XB-4-PCB-144 3.220 0.007 -8.45 5.63 46.97 
XB-5'-PCB-144 3.344 -0.006 -5.98 3.63 45.77 
XB-6-PCB-144 3.225 0.005 -8.80 5.91 46.28 
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XB-2'-PCB-145 3.292 -0.003 -6.45 4.40 45.72 
XB-2-PCB-145 3.214 0.009 -7.61 6.00 46.92 
XB-3-PCB-145 3.217 0.012 -5.98 6.39 47.66 
XB-4-PCB-145 3.242 0.004 -7.39 5.15 46.92 
XB-6-PCB-145 3.250 0.003 -8.04 5.32 46.23 
XB-2'-PCB-146 3.249 0.000 -7.76 5.02 46.09 
XB-2-PCB-146 3.223 0.006 -7.35 5.51 46.82 
XB-3-PCB-146 3.262 0.003 -7.76 4.83 46.82 
XB-4'-PCB-146 3.260 0.001 -7.68 4.87 46.85 
XB-5'-PCB-146 3.299 -0.002 -7.78 3.95 46.83 
XB-5-PCB-146 3.263 -0.001 -8.11 4.76 46.07 
XB-2'-PCB-147 3.276 -0.001 -6.37 4.69 45.78 
XB-3-PCB-147 3.240 0.005 -8.56 5.21 46.98 
XB-4'-PCB-147 3.336 -0.007 -6.36 3.64 45.78 
XB-2'-PCB-148 3.222 0.006 -8.67 5.82 46.08 
XB-2-PCB-148 3.242 0.006 -6.63 5.41 46.78 
XB-3-PCB-148 3.265 0.002 -6.98 4.80 46.80 
XB-4'-PCB-148 3.262 0.000 -8.03 5.14 46.13 
XB-5-PCB-148 3.287 -0.004 -7.19 4.32 46.05 
XB-2-PCB-149 3.266 0.009 -8.18 4.48 46.80 
XB-2'-PCB-149 3.271 0.000 -7.47 4.82 46.03 
XB-3-PCB-149 3.342 -0.004 -7.90 3.40 46.78 
XB-4'-PCB-149 3.278 0.000 -6.41 4.58 46.80 
XB-5'-PCB-149 3.268 0.003 -6.11 5.17 46.79 
XB-6-PCB-149 3.266 -0.001 -8.18 4.48 45.98 
XB-2-PCB-150 3.232 0.005 -6.34 5.64 46.75 
XB-3-PCB-150 3.329 -0.002 -6.81 3.64 46.76 
XB-4'-PCB-150 3.271 0.000 -6.90 4.94 46.07 
XB-6-PCB-150 3.259 0.000 -7.35 5.24 45.98 
XB-2'-PCB-151 3.315 -0.003 -6.20 3.97 45.77 
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XB-2-PCB-151 3.232 0.007 -9.10 5.64 47.01 
XB-3-PCB-151 3.240 0.004 -8.23 5.28 46.99 
XB-5'-PCB-151 3.357 -0.007 -5.89 3.97 45.79 
XB-2'-PCB-152 3.333 -0.004 -6.12 3.67 45.74 
XB-2-PCB-152 3.223 0.008 -7.18 5.90 46.99 
XB-3-PCB-152 3.242 0.005 -7.08 5.12 46.96 
XB-2-PCB-153 3.248 0.002 -7.96 5.08 46.09 
XB-4-PCB-153 3.260 0.001 -7.69 4.84 46.85 
XB-5-PCB-153 3.238 0.005 -7.27 5.57 46.83 
XB-2'-PCB-154 3.227 0.006 -8.48 5.62 46.04 
XB-2-PCB-154 3.257 0.002 -7.57 5.10 46.03 
XB-4'-PCB-154 3.254 -0.001 -8.55 4.98 46.11 
XB-4-PCB-154 3.266 0.000 -6.81 4.77 46.79 
XB-5-PCB-154 3.266 0.004 -6.31 5.19 46.81 
XB-2-PCB-155 3.247 0.002 -7.54 5.38 46.04 
XB-4-PCB-155 3.260 -0.001 -7.18 4.96 46.08 
XB-3-PCB-156 3.177 0.016 -8.70 7.46 47.63 
XB-4-PCB-156 3.179 0.014 -8.46 7.30 47.69 
XB-5-PCB-156 3.415 -0.005 -9.91 2.26 46.93 
XB-3'-PCB-156 3.284 0.003 -5.71 4.99 46.62 
XB-4'-PCB-156 3.461 -0.009 -6.70 2.40 46.58 
XB-3-PCB-157 3.202 0.012 -7.29 6.83 47.53 
XB-4-PCB-157 3.255 0.001 -8.54 4.90 46.77 
XB-3'-PCB-157 3.295 0.000 -6.98 4.06 46.74 
XB-4'-PCB-157 3.221 0.010 -6.44 6.44 47.54 
XB-3'-PCB-158 3.293 0.002 -5.07 4.85 46.58 
XB-3-PCB-158 3.177 0.014 -8.57 7.46 47.70 
XB-4'-PCB-158 3.456 -0.008 -5.70 2.52 46.54 
XB-4-PCB-158 3.215 0.007 -9.69 5.74 47.00 
XB-3'-PCB-159 3.279 -0.002 -6.93 4.77 45.86 
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XB-3-PCB-159 3.157 0.019 -8.91 7.96 47.65 
XB-4-PCB-159 3.169 0.016 -8.72 7.58 47.72 
XB-5-PCB-159 3.214 0.009 -9.02 6.25 46.97 
XB-3'-PCB-160 3.408 -0.009 -4.62 3.35 45.49 
XB-3-PCB-160 3.162 0.018 -9.07 7.82 47.79 
XB-4-PCB-160 3.142 0.022 -9.49 8.41 47.79 
XB-3'-PCB-161 3.294 -0.005 -6.19 4.50 45.84 
XB-4-PCB-161 3.188 0.010 -9.62 6.55 47.02 
XB-3-PCB-161 3.181 0.014 -8.59 7.36 47.73 
XB-6-PCB-161 3.215 0.006 -9.50 5.79 46.27 
XB-2-PCB-162 3.247 0.007 -9.98 4.77 46.73 
XB-3'-PCB-162 3.248 0.005 -7.00 5.60 46.75 
XB-3-PCB-162 3.256 0.003 -8.90 4.89 46.82 
XB-4'-PCB-162 3.219 0.009 -6.92 6.32 47.56 
XB-5-PCB-162 3.249 0.000 -8.95 5.21 46.11 
XB-4'-PCB-163 3.454 -0.008 -5.53 2.53 46.54 
XB-3-PCB-163 3.240 0.003 -9.28 5.22 47.00 
XB-3'-PCB-163 3.287 0.001 -4.74 4.88 46.58 
XB-3'-PCB-164 3.262 0.005 -6.15 5.26 46.72 
XB-3-PCB-164 3.366 -0.004 -8.67 3.01 46.79 
XB-4'-PCB-164 3.231 0.008 -5.34 6.03 47.51 
XB-2-PCB-164 3.204 0.008 -7.99 5.53 46.79 
XB-6-PCB-164 3.277 0.000 -8.95 4.40 46.00 
XB-2-PCB-165 3.195 0.009 -8.57 5.73 47.02 
XB-3'-PCB-165 3.295 -0.004 -6.05 4.37 45.84 
XB-3-PCB-165 3.230 0.005 -9.43 5.47 47.02 
XB-3-PCB-166 3.152 0.018 -9.64 7.90 47.78 
XB-4'-PCB-166 3.379 -0.008 -5.03 3.82 45.46 
XB-4-PCB-166 3.144 0.023 -9.39 8.46 47.78 
XB-4-PCB-167 3.243 0.002 -8.45 5.12 46.90 
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XB-5-PCB-167 3.240 0.004 -8.11 5.76 46.85 
XB-3'-PCB-167 3.230 0.006 -7.21 5.90 46.76 
XB-4'-PCB-167 3.221 0.010 -6.26 6.36 47.56 
XB-3'-PCB-168 3.426 -0.006 -7.19 2.64 46.73 
XB-4'-PCB-168 3.230 0.010 -5.82 6.24 47.51 
XB-2-PCB-168 3.221 0.004 -9.32 5.57 46.01 
XB-4-PCB-168 3.250 0.001 -9.53 5.37 46.18 
XB-3-PCB-169 3.530 -0.008 -8.73 1.60 46.76 
XB-4-PCB-169 3.200 0.010 -7.60 6.72 47.61 
XB-2-PCB-170 3.252 0.013 -10.82 5.01 46.97 
XB-2'-PCB-170 3.199 0.009 -7.77 5.95 46.77 
XB-3'-PCB-170 3.205 0.011 -6.96 6.69 47.56 
XB-3-PCB-170 3.173 0.018 -8.08 7.67 47.67 
XB-4'-PCB-170 3.294 -0.001 -8.43 4.10 46.76 
XB-4-PCB-170 3.187 0.016 -7.94 7.25 47.68 
XB-5-PCB-170 3.227 0.008 -8.90 5.84 46.95 
XB-3'-PCB-171 3.212 0.012 -6.51 6.59 47.54 
XB-3-PCB-171 3.175 0.016 -8.65 7.46 47.74 
XB-4'-PCB-171 3.297 -0.002 -7.69 4.05 46.72 
XB-4-PCB-171 3.212 0.006 -9.56 5.77 46.99 
XB-2'-PCB-172 3.209 0.007 -8.01 5.72 46.87 
XB-2-PCB-172 3.185 0.012 -8.70 6.34 47.00 
XB-3'-PCB-172 3.240 0.003 -8.52 5.28 46.85 
XB-3-PCB-172 3.164 0.018 -8.38 7.73 47.69 
XB-4-PCB-172 3.179 0.016 -8.23 7.45 47.71 
XB-5'-PCB-172 3.255 0.000 -8.73 4.89 46.12 
XB-5-PCB-172 3.215 0.008 -8.62 6.13 46.98 
XB-2'-PCB-173 3.253 0.004 -5.81 5.55 46.55 
XB-3'-PCB-173 3.417 -0.008 -6.29 2.94 46.55 
XB-3-PCB-173 3.144 0.021 -9.00 8.21 47.82 
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XB-4-PCB-173 3.141 0.022 -9.19 8.29 47.79 
XB-3'-PCB-174 3.335 -0.003 -8.47 3.46 46.81 
XB-3-PCB-174 3.178 0.015 -7.44 7.34 47.65 
XB-4-PCB-174 3.185 0.014 -7.32 7.12 47.66 
XB-5-PCB-174 3.268 0.002 -8.10 4.47 46.96 
XB-6'-PCB-174 3.272 0.000 -8.89 4.32 46.01 
XB-3'-PCB-175 3.258 0.002 -7.62 4.90 46.84 
XB-3-PCB-175 3.178 0.015 -8.25 7.25 47.76 
XB-4-PCB-175 3.185 0.009 -9.27 6.60 47.01 
XB-5'-PCB-175 3.258 -0.001 -7.66 4.91 46.09 
XB-6-PCB-175 3.212 0.006 -9.53 5.89 46.32 
XB-2'-PCB-176 3.216 0.008 -7.44 5.82 46.81 
XB-3'-PCB-176 3.384 -0.006 -7.74 2.81 46.78 
XB-3-PCB-176 3.188 0.013 -7.34 6.94 47.73 
XB-4-PCB-176 3.208 0.008 -8.57 5.97 46.97 
XB-6'-PCB-176 3.247 0.001 -8.28 5.18 46.00 
XB-2-PCB-177 3.212 0.010 -7.45 6.02 46.73 
XB-3'-PCB-177 3.237 0.004 -9.34 5.26 47.01 
XB-3-PCB-177 3.207 0.010 -6.40 6.61 47.54 
XB-4-PCB-177 3.273 0.001 -7.41 4.58 46.73 
XB-2-PCB-178 3.193 0.010 -9.26 6.08 46.81 
XB-3-PCB-178 3.232 0.006 -9.35 5.35 46.86 
XB-5-PCB-178 3.255 -0.002 -7.62 4.99 46.10 
XB-2'-PCB-178 3.196 0.010 -8.99 5.96 47.04 
XB-3'-PCB-178 3.229 0.006 -9.39 5.47 47.05 
XB-2'-PCB-179 3.219 0.008 -7.29 5.83 46.81 
XB-2-PCB-179 3.209 0.009 -8.48 6.13 47.00 
XB-3'-PCB-179 3.359 -0.004 -7.55 3.11 46.79 
XB-3-PCB-179 3.217 0.006 -8.24 5.93 47.01 
XB-6'-PCB-179 3.248 0.001 -7.91 5.09 46.01 
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XB-2'-PCB-180 3.228 0.003 -8.49 5.43 46.12 
XB-2-PCB-180 3.191 0.010 -9.09 6.07 46.97 
XB-3-PCB-180 3.167 0.017 -8.52 7.68 47.68 
XB-4'-PCB-180 3.250 0.001 -8.35 5.03 46.88 
XB-4-PCB-180 3.171 0.016 -8.32 7.68 47.71 
XB-5'-PCB-180 3.244 0.004 -7.94 5.50 46.87 
XB-5-PCB-180 3.214 0.005 -9.20 5.86 46.97 
XB-2'-PCB-181 3.252 0.000 -7.24 5.07 45.80 
XB-3-PCB-181 3.143 0.021 -9.49 8.16 47.82 
XB-4'-PCB-181 3.322 -0.005 -7.00 3.82 45.82 
XB-4-PCB-181 3.140 0.023 -9.33 8.49 47.80 
XB-2'-PCB-182 3.206 0.006 -9.27 6.10 46.09 
XB-2-PCB-182 3.207 0.010 -8.55 6.05 46.92 
XB-3-PCB-182 3.176 0.018 -7.58 7.37 47.67 
XB-4'-PCB-182 3.253 0.001 -8.70 5.23 46.17 
XB-4-PCB-182 3.181 0.014 -7.68 7.25 47.66 
XB-5-PCB-182 3.230 0.008 -7.66 5.88 46.96 
XB-2-PCB-183 3.162 0.017 -9.31 6.73 46.98 
XB-3-PCB-183 3.178 0.016 -8.54 7.27 47.76 
XB-4-PCB-183 3.207 0.007 -9.37 5.64 47.01 
XB-6-PCB-183 3.202 0.007 -9.86 6.18 46.31 
XB-2'-PCB-183 3.244 0.001 -8.42 5.32 46.04 
XB-4'-PCB-183 3.257 0.001 -7.40 4.94 46.84 
XB-5'-PCB-183 3.241 0.004 -6.98 5.48 46.84 
XB-2-PCB-184 3.178 0.012 -13.79 6.81 46.93 
XB-3-PCB-184 3.186 0.015 -7.56 6.99 47.73 
XB-4'-PCB-184 3.247 0.000 -8.19 5.16 46.12 
XB-6-PCB-184 3.217 0.006 -9.17 6.23 46.28 
XB-2'-PCB-185 3.288 -0.002 -6.86 4.42 45.77 
XB-5'-PCB-185 3.353 -0.007 -6.75 4.02 45.82 
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XB-2-PCB-185 3.157 0.017 -9.57 7.05 47.17 
XB-3-PCB-185 3.150 0.022 -8.86 8.26 47.84 
XB-4-PCB-185 3.135 0.024 -9.06 8.70 47.80 
XB-2'-PCB-186 3.279 -0.001 -6.86 4.54 45.76 
XB-2-PCB-186 3.192 0.013 -8.77 6.55 47.13 
XB-3-PCB-186 3.167 0.019 -7.66 7.62 47.80 
XB-4-PCB-186 3.154 0.021 -8.35 7.96 47.76 
XB-2'-PCB-187 3.250 0.000 -8.04 5.15 46.07 
XB-2-PCB-187 3.184 0.012 -9.12 6.21 47.03 
XB-3-PCB-187 3.229 0.004 -9.29 5.44 47.04 
XB-4'-PCB-187 3.259 0.001 -7.25 4.89 46.85 
XB-5'-PCB-187 3.243 0.003 -7.07 5.51 46.85 
XB-2'-PCB-188 3.230 0.004 -8.40 5.68 46.10 
XB-2-PCB-188 3.209 0.010 -8.48 6.16 47.01 
XB-3-PCB-188 3.248 0.004 -8.56 4.91 47.02 
XB-4'-PCB-188 3.264 0.000 -8.02 5.10 46.13 
XB-3-PCB-189 3.152 0.019 -9.75 8.14 47.68 
XB-4-PCB-189 3.156 0.016 -9.83 7.93 47.75 
XB-5-PCB-189 3.208 0.009 -9.83 6.36 47.01 
XB-3'-PCB-189 3.237 0.007 -7.50 6.12 46.81 
XB-4'-PCB-189 3.202 0.010 -7.50 6.97 47.60 
XB-3'-PCB-190 3.269 0.001 -5.72 5.14 46.61 
XB-4'-PCB-190 3.444 -0.008 -6.25 2.52 46.58 
XB-2-PCB-190 3.193 0.016 -11.90 6.15 47.16 
XB-3-PCB-190 3.138 0.020 -10.36 8.28 47.84 
XB-4-PCB-190 3.132 0.025 -10.20 8.82 47.83 
XB-2-PCB-191 3.149 0.015 -9.91 6.88 46.97 
XB-3'-PCB-191 3.250 0.005 -7.00 5.41 46.77 
XB-3-PCB-191 3.174 0.018 -9.22 7.68 47.76 
XB-4'-PCB-191 3.230 0.010 -5.89 6.14 47.55 
121 
 
XB-4-PCB-191 3.191 0.008 -10.57 6.32 47.06 
XB-5'-PCB-191 3.250 -0.001 -7.00 5.41 46.76 
XB-2-PCB-192 3.164 0.015 -10.31 6.67 47.19 
XB-3'-PCB-192 3.279 -0.002 -6.78 4.74 45.87 
XB-3-PCB-192 3.130 0.022 -10.45 8.56 47.86 
XB-4-PCB-192 3.125 0.027 -10.23 9.02 47.85 
XB-2-PCB-193 3.172 0.012 -9.42 6.33 47.03 
XB-3'-PCB-193 3.340 -0.003 -7.30 3.24 46.77 
XB-3-PCB-193 3.221 0.006 -10.16 5.59 47.06 
XB-4'-PCB-193 3.228 0.011 -5.96 6.26 47.56 
XB-2-PCB-194 3.172 0.012 -9.48 6.59 47.01 
XB-3-PCB-194 3.159 0.019 -9.17 7.94 47.71 
XB-4-PCB-194 3.166 0.016 -9.11 7.63 47.74 
XB-5-PCB-194 3.201 0.009 -9.49 6.48 47.01 
XB-2'-PCB-195 3.202 0.009 -8.25 6.05 46.74 
XB-3'-PCB-195 3.200 0.012 -7.08 6.80 47.57 
XB-3-PCB-195 3.135 0.022 -10.20 8.33 47.87 
XB-4'-PCB-195 3.334 -0.004 -8.23 3.41 46.76 
XB-4-PCB-195 3.130 0.024 -10.00 8.69 47.83 
XB-2'-PCB-196 3.150 0.017 -10.40 6.90 47.01 
XB-3'-PCB-196 3.163 0.018 -9.39 7.79 47.80 
XB-3-PCB-196 3.169 0.017 -8.62 7.57 47.70 
XB-4'-PCB-196 3.200 0.007 -10.22 6.04 47.05 
XB-4-PCB-196 3.167 0.015 -8.58 7.96 47.70 
XB-5-PCB-196 3.211 0.010 -8.61 6.26 47.00 
XB-6'-PCB-196 3.193 0.008 -10.81 6.40 46.32 
XB-3-PCB-197 3.176 0.016 -8.39 7.22 47.78 
XB-4-PCB-197 3.195 0.009 -9.61 6.24 47.02 
XB-6-PCB-197 3.207 0.007 -9.97 6.04 46.32 
XB-2'-PCB-198 3.207 0.008 -8.28 6.08 46.82 
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XB-2-PCB-198 3.141 0.017 -10.73 7.08 47.21 
XB-3-PCB-198 3.126 0.023 -10.18 8.69 47.88 
XB-4-PCB-198 3.124 0.027 -10.12 9.03 47.85 
XB-5'-PCB-198 3.249 -0.001 -8.36 5.03 46.13 
XB-3'-PCB-198 3.220 0.007 -8.29 5.73 46.89 
XB-2'-PCB-199 3.209 0.011 -12.24 5.71 47.05 
XB-2-PCB-199 3.186 0.012 -9.18 6.52 46.96 
XB-3'-PCB-199 3.185 0.009 -10.04 6.79 47.09 
XB-3-PCB-199 3.163 0.017 -8.41 7.73 47.71 
XB-4-PCB-199 3.175 0.017 -8.19 7.50 47.70 
XB-5-PCB-199 3.240 0.004 -8.97 4.97 47.01 
XB-2'-PCB-200 3.195 0.009 -7.79 6.38 46.81 
XB-3'-PCB-200 3.360 -0.004 -8.20 3.05 46.84 
XB-3-PCB-200 3.141 0.020 -8.88 8.17 47.86 
XB-4-PCB-200 3.129 0.024 -9.49 9.17 47.81 
XB-6'-PCB-200 3.274 -0.002 -8.84 4.50 46.04 
XB-2-PCB-201 3.159 0.016 -9.60 7.20 46.99 
XB-3-PCB-201 3.177 0.014 -8.24 7.40 47.77 
XB-4-PCB-201 3.199 0.008 -9.43 6.09 47.03 
XB-6-PCB-201 3.262 0.001 -12.31 4.80 46.31 
XB-3'-PCB-201 3.229 0.004 -9.14 5.28 47.07 
XB-2-PCB-202 3.180 0.010 -9.29 6.61 47.03 
XB-3-PCB-202 3.208 0.007 -9.27 6.18 47.07 
XB-2'-PCB-203 3.319 -0.003 -11.85 3.97 46.07 
XB-2-PCB-203 3.133 0.019 -10.80 7.52 47.19 
XB-3-PCB-203 3.137 0.021 -10.33 8.32 47.88 
XB-4'-PCB-203 3.223 0.004 -8.28 5.85 46.88 
XB-4-PCB-203 3.118 0.027 -10.12 9.21 47.85 
XB-5'-PCB-203 3.237 0.003 -7.60 5.53 46.88 
XB-2'-PCB-204 3.209 0.005 -9.14 6.04 46.11 
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XB-2-PCB-204 3.203 0.011 -12.46 5.82 47.16 
XB-3-PCB-204 3.140 0.020 -9.46 8.17 47.86 
XB-4'-PCB-204 3.255 0.001 -8.68 5.25 46.16 
XB-4-PCB-204 3.132 0.022 -9.53 8.52 47.81 
XB-2-PCB-205 3.122 0.020 -11.58 7.44 47.20 
XB-3'-PCB-205 3.223 0.005 -7.64 5.85 46.80 
XB-3-PCB-205 3.127 0.022 -10.90 8.65 47.90 
XB-4'-PCB-205 3.220 0.012 -6.65 6.44 47.59 
XB-4-PCB-205 3.109 0.029 -11.02 9.62 47.88 
XB-2'-PCB-206 3.214 0.011 -15.59 5.54 46.97 
XB-2-PCB-206 3.188 0.014 -13.84 6.09 47.22 
XB-3'-PCB-206 3.158 0.019 -9.16 7.93 47.74 
XB-3-PCB-206 3.128 0.024 -11.05 8.61 47.92 
XB-4'-PCB-206 3.205 0.015 -12.38 5.87 47.73 
XB-4-PCB-206 3.109 0.029 -10.98 9.56 47.87 
XB-5'-PCB-206 3.200 0.010 -9.13 6.51 47.03 
XB-2'-PCB-207 3.145 0.017 -10.24 7.58 47.00 
XB-3'-PCB-207 3.165 0.016 -9.05 7.68 47.79 
XB-3-PCB-207 3.136 0.022 -10.08 8.28 47.90 
XB-4'-PCB-207 3.205 0.007 -9.94 5.87 47.05 
XB-4-PCB-207 3.121 0.027 -9.92 9.09 47.84 
XB-6'-PCB-207 3.189 0.007 -10.52 6.51 46.32 
XB-2'-PCB-208 3.172 0.012 -9.93 6.83 47.04 
XB-2-PCB-208 3.136 0.018 -10.77 7.71 47.20 
XB-3'-PCB-208 3.216 0.007 -9.71 5.67 47.10 
XB-3-PCB-208 3.125 0.022 -10.03 8.63 47.90 
XB-4-PCB-208 3.116 0.027 -10.17 9.31 47.86 
XB-2-PCB-209 3.129 0.019 -11.62 7.94 47.21 
XB-3-PCB-209 3.127 0.022 -10.77 8.56 47.92 
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